

Memorial Sloan Kettering Cancer Center (MSK)

Curriculum Vitae

Name: Deborah Schrag, MD, MPH

Signature:



Date of Preparation: August 14, 2023

A. PERSONAL DATA

Current Office address:	Memorial Sloan Kettering Cancer Center Department of Medicine 1275 York Avenue, NY, NY 10065
Office telephone:	212-639-5851
Office fax:	
Home address:	2 Scott Street, Cambridge, MA 02138
Cell phone:	617-416-5194
Email address - Work:	schragd@mskcc.org
Is your eligibility to work in the U.S. based on an employment visa?:	No

B. EDUCATION

Academic Degree(s)

Degree	Institution name & Location	Dates attended	Year Awarded
B.A. History	Harvard University, Cambridge, MA	09/82-06/86	1986
M.D. Medicine	Columbia University Medical School, New York, NY	08/87-05/91	1991

Degree	Institution name & Location	Dates attended	Year Awarded
M.P.H. Health Policy and Management	Harvard University School of Public Health, Boston, MA	07/96-02/98	1998

Other Education Experiences

Description	Institution Name & Location	Dates attended
Brigham and Women's Hospital Leadership Program Fellow, Health Care Economics and Leadership Training with MBA-level coursework	Harvard Business School, Boston, MA	09/08-06/09
Executive Training, Intensive summer course for health system leaders	Harvard School of Public Health, Boston, MA	07/13-09/13

C. POSTDOCTORAL TRAINING

Title	Institution Name & Location	Dates
Intern, Medicine	Brigham and Women's Hospital, Boston, MA	06/91-06/92
Clinical Fellow, Medicine	Harvard Medical School, Boston, MA	06/91-06/96
Junior Assistant Resident, Medicine	Brigham and Women's Hospital, Boston, MA	06/92-06/93
Senior Medical Resident, Medicine	Brigham and Women's Hospital, Boston, MA	06/93-06/94
Chief Medical Resident, Medical Service	West Roxbury VA Hospital, Boston, MA	06/94-10/94
Fellow, Medical Oncology	Dana-Farber Cancer Institute, Boston, MA	06/94-06/98
Post-Doctoral Fellow, Cancer-Related Health Services Research	Dana-Farber Cancer Institute, Boston, MA	06/94-06/98

D. PROFESSIONAL POSITIONS & EMPLOYMENT

Academic Appointments

Title	Institution, City and State	Dates
Instructor, Medicine	Harvard Medical School, Boston, MA	7/1996- 1/1999
Assistant Member Level I, Epidemiology and Biostatistics and Medicine	Memorial Sloan Kettering Cancer Center, New York, NY	2/1999-6/2000
Assistant Member Level II, Epidemiology and Biostatistics and Medicine	Memorial Sloan Kettering Cancer Center, New York, NY	7/2000-9/2005
Assistant Professor, Public Health	Weill-Cornell Medical College, New York, NY	1/2000-9/2005
Associate Member, Epidemiology and Biostatistics and Medicine	Memorial Sloan Kettering Cancer Center, New York, NY	9/2005-12/2007
Associate Professor, Public Health and Medicine	Weill-Cornell Medical College, New York, NY	1/2005-12/2007
Associate Professor, Medicine	Harvard Medical School, Boston, MA	7/2008- 6/2013
Professor (with Tenure), Medicine	Harvard Medical School, Boston, MA	7/2013- 6/2021
Member	Memorial Sloan Kettering Cancer Center, New York, NY	8/2001—current
Professor of Medicine	Weill Cornell Medical College, New York, NY	2/12022-current

Hospital Appointments

Title	Institution, City and State	Dates
Attending Physician, Medicine	Brigham and Women's Hospital, Boston, MA	07/96-06/99
Attending Physician, Medicine	Dana-Farber Cancer Institute, Boston, MA	07/97-01/99
Clinical Assistant Physician, Medicine (Solid Tumor-Gastrointestinal Oncology)	Memorial Sloan Kettering Cancer Center, New York, NY	02/99-06/00

Title	Institution, City and State	Dates
Assistant Attending Physician, Medicine (Solid Tumor-Gastrointestinal Oncology)	Memorial Sloan Kettering Cancer Center, New York, NY	07/00-09/05
Associate Attending Physician, Medicine (Solid Tumor-Gastrointestinal Oncology)	Memorial Sloan Kettering Cancer Center, New York, NY	09/05-12/07
Consult Attending, Epidemiology and Biostatistics	Memorial Sloan Kettering Cancer Center, New York, NY	01/08-12/13
Attending Physician, Medical Oncology	Dana-Farber Cancer Institute, Boston, MA	01/08-12/11
Associate Physician, Medicine	Brigham and Women's Hospital, Boston, MA	01/08-07/21
Senior Attending Physician, Medical Oncology	Dana-Farber Cancer Institute, Boston, MA	01/12-07/21
Attending Physician, Medicine	Memorial Sloan Kettering Cancer Center, New York, NY	August 16, 2021-current
Chair, Department of Medicine	Memorial Sloan Kettering Cancer Center, New York, NY	August 16, 2021—current

Other Professional Positions & Employment

Major Committee Assignments and Administrative Leadership Positions

Title	Institution, City and State	Dates
Chair, Committee on Use of Institutional Clinical Data for Research	Memorial Sloan-Kettering Cancer Center New York, NY	2002-2006
Co-Chair, Junior Faculty Council (with Ron DeMatteo)	Memorial Sloan-Kettering Cancer Center New York, NY	2001-2003
Deputy Associate Director, Population Sciences	Dana-Farber / Harvard Cancer Center (DF/HCC), Boston, MA	2008-2017
Steering Committee	Dana-Farber / Harvard Cancer Center (DF/HCC), Boston, MA	2011-2017
Chair, Clinical Data Governance	Dana-Farber Cancer Institute, Boston MA	2011-2019

Title	Institution, City and State	Dates
Chief, Division of Population Sciences and the McGraw Patterson Center for Population Sciences	Dana-Farber Cancer Institute, Boston, MA	2013-2021
Leader, Center for Outcomes and Policy Research	Dana-Farber Cancer Institute, Boston, MA	2013-2021
Founding Chair, Cancer Care Delivery Research Program	Dana-Farber Harvard Cancer Center, Boston, MA	2014-2021
Core Faculty Steering Committee	Program on Clinical Effectiveness, Harvard Chan School of Public Health	2009-2017
Member, Committee on Promotions and Appointments	Dana-Farber Cancer Institute, Boston, MA	2014-2017
Co-Chair, Committee on Promotions and Appointments (with Dr. Todd Golub)	Dana-Farber Cancer Institute, Boston, MA	2018-2021
Chair, Search for Chief Research Information Officer	Dana-Farber Cancer Institute, Boston, MA	2015
Chair of three ad hoc committees for Professorial promotion	Harvard Medical School, Boston, MA	2015-2020
Founding PI, Training in Oncology Focused Population Sciences (NCI-funded T32)	Dana-Farber / Harvard Cancer Center (DF/HCC), Boston, MA	2017-2021

National Committee Assignments

Title	Institution, City and State	Dates
Co-Chair Cancer Control and Health Outcomes	Cancer and Leukemia Group B (CALGB), Chicago, IL	2004-2009
Chair, Colorectal Cancer (CRC) Database	National Comprehensive Cancer Network (NCCN), Fort Washington, PA	2005-2008
Elected Member, Board of Directors	American Board of Internal Medicine (ABIM), Philadelphia, PA	2007-2012

Title	Institution, City and State	Dates
Elected Member, Board of Directors	American Society of Clinical Oncology	2008-2012
Executive Committee	Cancer and Leukemia Group B (CALGB), Chicago, IL	2008-2013
Chair, Colorectal Cancer Committee	National Comprehensive Cancer Network, Fort Washington, PA	2008-2013
Associate Editor, JNCI	Journal of the National Cancer Institute, Washington DC	2012-2014
Member, National Cancer Policy Forum	Institute of Medicine, National Academies Washington DC	2014-2020
Associate Editor, JAMA	Journal of the American Medical Association, Chicago, IL	2014-present
Member	Rectal-Anal Cancer Task Force, NCI Cancer Treatment and Evaluation Program	2015-present
Member	Board of Trustees, Alliance for Clinical Trials in Oncology, Chicago, IL	2016-2020
Co-Chair	American Association of Cancer Research's Project GENIE: Biopharma Consortium	2018-2021
Member	Mayo Clinic External Advisory Board	2023-
Member	Lineberger External Advisory Board Meeting	2023-
Member	OICR Scientific Advisory Board	2023-

E. LICENSURE, BOARD CERTIFICATION

Licensure:

State	Number	Date of issue	Date of Expiration
New York	212739-1	01/17/1999	05/31/2023

State	Number	Date of issue	Date of Expiration
Massachusetts	77651	05/12/1993	04/02/2022

DEA number:	BS3636567
NPI number:	1922079870

Board Certification

Full Name of Board	Certificate # 155377	Dates of Certification)
American Board of Internal Medicine	155377	1995-2005
American Board of Internal Medicine, Medical Oncology	155377	1997-2007
American Board of Internal Medicine	155377	2005-2015
American Board of Internal Medicine, Medical Oncology	155377	2007-2017
American Board of Internal Medicine, Medical Oncology	155377	2017-2027

F. INSTITUTIONAL/HOSPITAL AFFILIATION

Current Primary Hospital Affiliation:	Memorial Sloan Kettering Cancer Center, New York, NY
Other Hospital Affiliations:	Weill Cornell Medical College, New York, NY

G. EMPLOYMENT STATUS

Name of Current Employer(s):	Memorial Sloan Kettering Cancer Center, New York, NY
Current Employment Status:	Full-time salaried by Memorial Sloan Kettering Cancer Center, New York, NY

H. HONORS, AWARDS

<i>Name of Award</i>	<i>Organization</i>	<i>Year Awarded</i>
Magna Cum Laude, Thesis Prize	Harvard University	1986
Katherine Ireland Fellowship	Harvard University	1986-1987
Alpha Omega Alpha	Columbia University	1991
Brad Patterson Award	Dana-Farber Cancer Institute	1996
Young Investigator Award	American Society of Clinical Oncology	1996-1998
Rising Star Research Award	Medical Foundation	1997-1999
Clinical Research Training Award	American Cancer Society	1999
Boyer Award for Excellence in Clinical Research	Memorial Sloan-Kettering Cancer Center	2002
Elizabeth and Felix Rohatyn Chair for Junior Faculty	Memorial Sloan-Kettering Cancer Center	2003-2007
Elected member, Fellow of the American Society of Clinical Oncology	American Society of Clinical Oncology	2012
Claire W. and Richard P. Morse Research Award	Dana-Farber Cancer Institute	2013
Housestaff Teaching Award and Recognition for contributions to career development	Brigham and Women's Hospital	2009, 2011, 2014
Research mentorship award	Harvard Chan School of Public Health Clinical Effectiveness Program	2012
Fellow of the American Society of Clinical Oncology	American Society of Clinical Oncology	2013
Recipient of the Richard L. Schilsky Achievement Award	Alliance for Clinical Trials in Oncology	2016
Elected Member	Association of American Physicians (AAP)	2016
Elected Member	Mayo Clinic External Advisory Committee	2023

ASCO-ACS Cancer Prevention Award	ASCO	2023
Giants of Cancer Care	OncLive	2023

I. PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS

<i>Organization</i>	<i>Date</i>
<i>American Society of Clinical Oncology</i>	
Associate Member	1996-1997
Member	1998-present
Member, Health Services Research Committee	2000-2003
Member, Guideline Committee for Stage II Colon Cancer	2002-2004
Chair, Technology Assessment: Chemo Sensitivity Assays	2002-2005
Chair-Elect, Chair, Past-Chair, Health Services Committee	2003-2006
Member, National Initiative on Cancer Care Quality Advisory Group	2004-2006
Member, Quality Advisory Group	2005-2008
Member, Program Committee, Health Services Track	2005-2008
Member, Finance Committee	2007-2010
Member, Quality of Care Committee	2007-2011
Member, Board of Directors	2008-2011
Member, Task Force on Costs of Care Committee	2008-2013
Member, Cancer Health Disparities Committee	2008-2014
Member, Quality Office Practice Initiative (QOPI) Steering Group	2009-2013
Member, Special Awards Selection Committee	2010-2012
Member, Cancer LinQ Data Governance Oversight Committee	2013-2017
Chair, Data Access Subcommittee of the DGOC	2014-2016
Member, Cancer Education Committee	2010, 2014, 2016
Member, Guidelines Review Committee	2018-2021
Co-Chair Cancer and Covid-19 Task Force	2020-2021

<i>Society for Medical Decision making</i> Program planning committee, Education committee, Reviewer, Speaker	1996-2017
<i>Academy Health</i> Track leader, reviewer, Chair, Value Frameworks, Panel	2008-present
<i>American Association of Cancer Research</i> Health Disparities Committee Member, Cancer Policy and Government, Relations, Co-Chair, Health Disparities Meeting, Committee Member, Project GENIE Steering Committee, Project-GENIE BPC co-PI	2012-present

J. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES

MSK Activity: <i>Anticipated</i>	Percent Effort (%)	Does the activity involve MSK students/research trainees? (Yes/No)
Teaching	5%	Yes
Clinical	10%	Yes
Administrative	60%	Yes
Research	25%	Yes
Total	100%	N/A

K. EDUCATIONAL CONTRIBUTIONS

Teaching

Didactic Teaching

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Various topics in Cancer Epidemiology, Health Services Research Methods and Population Science	Medical, surgical oncology fellows, residents, and medical students/ Memorial Sloan Kettering Cancer Center 20 hours per year	1999-2003

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Supervision of 1-2 masters' level statisticians/Memorial Sloan Kettering Cancer Center	4 hours per week	1999-2003
Supervision of 2 postdoctoral fellows in health services research/Memorial Sloan Kettering Cancer Center	4 hours per week	1999-2003
Supervision of 3 postdoctoral fellows in health services research/Memorial Sloan Kettering Cancer Center	4-8 hours per week	2004-2007
Co-Supervision of 3-5 postdoctoral fellows in clinical research/ Memorial Sloan Kettering Cancer Center	16 hours a month	2004-2007
Project-specific mentorship for 5-6 students in Clinical Effectiveness Program/Harvard School of Public Health each year	Physicians in MPH training program 64 hours per year	2008-2020
Supervision of 1-3 postdoctoral fellows in health services research/Brigham and Women's Hospital/Dana-Farber Cancer Institute	8 hours per week	2008-2021
Doctoral thesis advisory committee/Harvard School of Public Health, Department of Epidemiology, Center for Decision Sciences and Department of Healthcare Policy and Management	PhD Candidates in health policy, epidemiology, statistics and other public health disciplines 10 hours per year	2012, 2014, 2017, 2018, 2020, 2021
Faculty-Harvard Medical School Health Policy Unit	Medical and Dental students 2 hours per year	2010-2013
Core Faculty-Epidemiology 208/Harvard Chan School of Public Health	Post-doctoral students 4 hours per year	2008-2020
Faculty-Epidemiology 276	Post-doctoral students 2 hours per year	2011-2014
Faculty-Epidemiology 253	Post-doctoral students	2014-2020

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
	3 hours per year	
Manuscript preparation-JAMA Network Editor Tips	Clinical residents, fellows and early career stage faculty 3 hours per year	2016-2018

Clinical Teaching

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Inpatient Oncology Attending/Brigham and Women's Hospital	150 hours per year	1997-1998
Inpatient Primary Attending for an Inpatient Gastrointestinal Oncology Unit/Memorial Sloan-Kettering Cancer Center	300 hours per year	1999-2004
Clinical mentor to oncology fellow/Memorial Sloan-Kettering Cancer Center	300 hours per year	1999-2007
Clinical mentor to international and second- or third-year fellows/Memorial Sloan-Kettering Cancer Center	30 hours per year	1999-2007
Clinical mentor to junior and senior medical and surgical residents/Memorial Sloan-Kettering Cancer Center	100 hours per year	1999-2007
Inpatient Consult Attending/Memorial Sloan-Kettering Cancer Center	25 hours per year	2000-2007
Inpatient Primary Attending/Memorial Sloan-Kettering Cancer Center	150 hours per year	2004-2007
Inpatient Oncology Attending/Brigham and Women's Hospital	120 hours per year 2 weeks per year	2008-2020
Consult Attending/Brigham and Women's Hospital/Dana-Farber Cancer Institute	60 hours per year	2008-2021
Inpatient Oncology and Consult Attending/Brigham and Women's Hospital/Dana-Farber Cancer Institute	1-2 weeks per year	2008-2021

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Inpatient Oncology Attending/Memorial Hospital, New York, NY	1-2 weeks per year	2021-current

Continuing Education and Professional Education as Teacher

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
HPM 286 Milton Weinstein PhD's Decision Analysis Course, Harvard School of Public Health	60 MPH students and clinic fellows	1996-1997
Introductory Epidemiology and US Health Care System, Weill-Cornell Medical College	30-40 medical students	2001-2006
Changing the Culture of Documentation to Foster Quality and Efficiency, Not Billing, Memorial Sloan-Kettering Cancer Center	150 medical oncologists, fellows, and residents	2007
HPM 299 Summer Course with John Ayanian, Research with Large Databases	50 physicians in Clinical Effectiveness Program	2008
EPI 1257 Advanced Seminar in Cancer Epidemiology, Harvard School of Public Health	15 graduate students	2008
EPI 208, Core Faculty, Harvard School of Public Health	24-36 graduate students	2009-2020
Methods for Comparative Effectiveness Research, Harvard School of Public Health	30-70 graduate students	2012-2020
HPM 276 Introduction to Methods and Applications in Health Services Research Course, Harvard School of Public Health	20-30 graduate students	2014-2021
HPM 276 Summer Course with Sebastian Schneeweiss and Michael Fischer, Large Scale Administrative Database Methods	50 physicians in Clinical Effectiveness Program	2014-2021
EPI 253 Effectiveness Research with Longitudinal Healthcare Databases, Harvard School of Public Health	X	2014-

Continuing Education and Professional Education as Teacher

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
1-2 continuing education courses per year, topics related to gastrointestinal cancer or quality measurement in oncology New York, NY	1 talk in single course 10-15 times	2000-2007
Ad Hoc Lectures on GI Oncology Topics: Preparation for Board Review, Highlights of ASCO, What's new in GI Oncology, the most important GI oncology publications Memorial Sloan Kettering Cancer Center	MDs, RNs, Alumni, Pediatricians, Radiation oncologists, Interventional radiologists, Visiting lecturers 10-15 hours per year	2001-2007
Data Sources and Methods in Cancer-Related Outcomes Research Memorial Sloan-Kettering Cancer Center	35-60 surgical oncologists 2 hours per year	2002-2006
Update on Medical Management of Metastatic Colorectal Cancer Memorial Sloan-Kettering Cancer Center	35-60 surgical oncologists 1-2 hours per year	2002-2007
Quality Measurement in Oncology Memorial Sloan-Kettering Cancer Center	30 multidisciplinary clinician groups, MDs/RNs 3 hours per year	2003-2007
Outcomes and Quality Measurement in GI Oncology Memorial Sloan-Kettering Cancer Center	30 multidisciplinary clinician groups MDs/RNs 3 hours per year	2003-2007
Economics of Cancer Care Delivery, Professional Development Course for Medical Oncology PRIMED Course	1 talk in single course 5 times Los Angeles, CA New York, NY	2007-2008
Comparative Effectiveness and Medical Oncology Practice PRIMED Course	1 talk in single course 5 times Miami, FL, New York, NY	2009-2013
Teaching sessions at GI oncology and colorectal surgery meetings primarily on rectal cancer.	San Francisco, (GI ASCO, ACS and ASCRS) Barcelona (GI ESMO)	2014-2020
Teaching sessions on pragmatic trial designs at annual PCORI meetings and at Academy Health	Washington, DC	2014-2018
Various teaching sessions on "Real World Data" standards and clinical endpoints measurements	NIH Workshops, Cooperative Group Meetings of Alliance, SWOG	2014-2020
Teaching sessions on "How to prepare a manuscript for JAMA" held as part of local and national conferences	ASCO, ESMO, PCORI, ASPO meetings (in some, not all years)	2014-2019

Community Education and Patient Outreach

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Greenwich Village Community Board/Participant and volunteer consultant Consulted on health issues facing residents of Greenwich Village and North of Houston Street (NOHO) neighborhood in the wake of 09/11.	Peers	2001-2007
Public School 41 and Public School 3, New York City public schools/Volunteer medical educator	Elementary school students	2001-2007
New York City Department of Health Emergency Preparedness Team/Volunteer	Local government	2001-2007
Participated in trainings and disaster management established in response to 09/11. Participated in drills with simulated episodes of anthrax, flu, terrorism.	Local government	2001-2007
Ethical Culture Fieldston School, New York City/Volunteer Mentor-Careers in Public Health and Research	High school students	2001-2007
Sustaining Member of “El Sistema” a Program to Support Music Education in Somerville and Brighton Public Schools	Peers	2010-2016
Volunteer, Parents Association, Boston Youth Symphony Orchestra	Peers	2010-2016
Advisor, Somerville and Cambridge MA Public Schools Wellness and Cancer Prevention Education	Elementary school students	2011-2017
Fundraiser, participant and team organizer in the annual Jimmy Fund Walk Team	Peers	2011-2020
Fundraiser and participant in the annual “Pan Mass Challenge” Bicycle Ride	Peers	2015-2020
Volunteer, Counting Everyone Project—US. Census Cambridge MA—Community Outreach	Neighbors	2019
Advisor, Community Mobilization during SARS-CoV2-Public Health Commission, Cambridge MA	Local government	2020

L. CLINICAL PRACTICE, INNOVATION, and LEADERSHIP

Clinical Practice

<i>Duration</i>	<i>Name/Location of Practice</i>	<i>Type of Activity</i>	<i>Level of Activity</i>
1999-2007	Medical Oncology, Memorial Sloan-Kettering Cancer Center	Outpatient Clinic	1-2 days per week
1999-2007	Medical Oncology, Memorial Sloan-Kettering Cancer Center	Inpatient Attending	1 month per year
2008-2015	Medical Oncology, Dana-Farber Cancer Institute	Outpatient Clinic	1.5 day per week
2008-2013	Oncology "A" team (Housestaff), Brigham and Women's Hospital	Inpatient Attending	4 weeks per year
2015-2021	Medical Oncology Dana-Farber Cancer Institute	Outpatient Clinic	1 day per week
2014-2021	Oncology "A" team (Housestaff, intensive teaching) Brigham and Women's Hospital	Inpatient Attending	2 weeks per year
2007-2021	Consult attending, Brigham and Women's Hospital	Consult Attending (primarily from surgery)	2 weeks per year
2017-2021	Medical Oncology Dana-Farber Cancer Institute	Outpatient Clinic	0.5 day per week
2017-2021	Dana Farber Inpatient Unit and Brigham and Women's Hospital	Inpatient Attending	1-2 weeks per year 3 weekends per year
2021—current	Memorial Hospital, New York, NY	Inpatient Attending	1-2 weeks per year

Clinical Innovations

<i>Date Innovation Launched</i>	<i>Title of Innovation</i>	<i>Role</i>	<i>Short Description of the influence on clinical care or practice management</i>
2003	Cancer Treatment Plans and Chemotherapy Treatment Summaries templates	Development of models of care delivery	Spearheaded and developed templates for “Cancer Treatment Plans” and “Chemotherapy Treatment Summaries” to facilitate care coordination. Author of white paper on this topic published on the ASCO website. The treatment summary initiative has been endorsed by multiple organizations including ASCO and the Institute of Medicine.
2005	Symptom Tracking and Reporting (STAR) at Memorial Sloan-Kettering Cancer Center	Development of treatment of disease	Co-developer of Symptom Tracking and Reporting (STAR) with primary mentee Ethan Basch, MD. This is a web-based on-line interface for evaluating patient toxicity and adverse symptom events during chemotherapy. The system is now integrated in multiple clinics at MSKCC and facilitates between visit reporting. It is also integrated alongside phase III CALGB clinical trials to compare patient and physician perspectives on symptom events. The National Cancer Institute has funded an extension of this system, the PRO-CTCAE, as its standard platform for patient reported outcomes alongside clinical trials.
2005	Cetuximab toxicity	Development of treatment of disease	First to recognize and report that the drug cetuximab may be associated with clinically severe hypomagnesemia (publication in the JNCI). This resulted in a change in the FDA package labeling.
2007	Selective Use of Radiation for Locally Advanced Rectal Cancer	Development of new model of care being tested in national clinical trial that completed accrual	Pelvic radiotherapy has been a critical component of treatment for locally advanced stage II/III rectal cancer since 1990 because it reduces pelvic recurrence, a morbid event. However, in the intervening years, both surgical technique for TME and systemic chemotherapy options have improved. Moreover, a large European trial demonstrated that administration of pelvic radiation in the neoadjuvant setting is superior. As a result, there is potential for overtreatment. Designing trials to “do less” and streamline care rather than to do more are challenging. At MSKCC, designed and executed a pilot phase II trial in collaboration with multidisciplinary team to selectively use pelvic radiation. Three year results of this study are so promising that the concept is now being validated and tested in the context of a phase II/III NCI

<i>Date Innovation Launched</i>	<i>Title of Innovation</i>	<i>Role</i>	<i>Short Description of the influence on clinical care or practice management</i>
			sponsored trial (PROSPECT) that has been endorsed by other cooperative groups including National Cancer Information Center (NCIC), Radiation Therapy Oncology Group (RTOG), Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG) and The National Surgical Adjuvant Breast and Bowel Project (NSABP) as well as by international collaborators. This trial opened across the US in Spring 2012.
2013	The National Cancer Institute's Patient Reported Outcomes- PRO-CTCAE	Development of application of technologies	I have served as one of the national leader's (along with my former mentee, Dr. Ethan Basch who served as Project PI) on the NCI's project to develop a streamlined approach to capture, storage, analysis and reporting of patient reported outcomes. The goal is to develop a robust and transparent system that can be integrated into clinical trials, routine care and can be used in the regulatory review and approvals process coordinated by the FDA. In 2015 the PRO-CTCAE platform was recognized by the FDA as a validated standard for regulatory decisions reliant on patient-reported outcomes. The system has now been used in over 300 clinical trials worldwide. PRO-CTCAE has been translated into more than 20 languages.
2017	<i>PRISSMM: Phenomic Data Standards and Tools</i>	Development of application, software and algorithms	PRISSMM is a set of data standards for ascertaining disease status from Electronic Health Records. PRISSMM is a suite of tools that includes definitions, data standards, a REDCAP database, training materials, software and algorithms that enable estimation of Real-World Outcomes of cancer treatment including real world recurrence, real world progression, progression and disease-free survival to be estimated reliably in multi-institutional projects that require curation. PRISSMM is a labeling strategy for "ground truthing" the unstructured free text notes that predominate in electronic health records and provides a framework for teaching machines to perform record curation in automated fashion using deep learning techniques. PRISSMM is the primary data curation strategy used in the American Association of Cancer Research's Project GENIE and is being adopted by

<i>Date Innovation Launched</i>	<i>Title of Innovation</i>	<i>Role</i>	<i>Short Description of the influence on clinical care or practice management</i>
			the NCI, tumor registries and cancer centers in the US, Canada and Europe
2018	<i>eSyM-Integrated PRO capture in patient portals</i>	Development of application of technologies	I conceived and led a multi-disciplinary team to build and integrate a platform to capture symptom reports between clinical encounters into the patient portal of Epic, the dominant US electronic health records vendor. The system, eSyM is now live at 6 cancer centers across the US and has been introduced into Epic's platform of offerings so that it can be installed by other centers to augment chronic disease management. This system is fully integrated into the Epic health record and not a standalone or "sidecar" model which enhances the experience for both clinician and patient users.
2020	<i>"Real World" Endpoints</i>	Development of application of technologies	Developed method for estimation of "real world" clinical endpoints that can be abstracted from electronic health record unstructured and structured data. The RECIST criteria provide a framework for identifying progression and response from imaging data. I led development of a toolbox to identify progression, response, recurrence and site of metastatic disease from electronic health record data.

M. RESEARCH

I am a population scientist and health services researcher and have held continuous NCI funding since receiving a K award in 1998. The questions that have motivated me are, how do we make cancer treatments work well outside of controlled experimental conditions? How do we ensure treatments achieve maximal impact on population health? How do we make care efficient and equitable? I have approached these core questions by developing and applying methods to evaluate the effectiveness of cancer treatments from observational data sources. Recently, the term "real world data" has come into vogue, but this is really a synonym for observational data where application of appropriate methods is required to avoid faulty inferences. I have expertise in measuring the quality of cancer care, cancer economics, and forecasting the impact of policies on cancer mortality. I am known as a leader in the field of patient-reported outcomes. I am a co-developer, with Ethan Basch of the PRO-CTCAE system for eliciting adverse events directly from patients. This body of work has shown that systematic tracking can decrease symptom burden and acute care needs. PRO-CTCAE assessments have been integrated into hundreds of clinical trials and this system is recognized by

the FDA as a regulatory standard for drug approval. I also have experience developing interventions and leading pragmatic clinical trials. I conceived and executed an NCI-sponsored randomized trial in locally advanced rectal cancer that met its accrual target and is awaiting data maturation and release by the data safety and monitoring board. I currently lead an NCI-funded Moonshot award to extend PRO-CTCAE to the routine care context. My team and I have worked with the Epic Corporation to develop eSyM, a secure symptom tracking system for population management that has been integrated into the electronic health records of six US health systems.

At MSK, I intend to continue research in cancer-focused population sciences. I intend to build a dry laboratory focused on designing and implementing interventions that optimize the delivery of cancer care. From 1996 when I completed fellowship to the present, cancer treatment has transitioned from the hospital to the outpatient clinic. Digital technologies, telehealth, oral and subcutaneous treatments as well as cultural shifts will enable more cancer care to shift from the outpatient clinic to home. This shift will be fraught with challenges but has great potential to improve the effectiveness and efficiency of care. I anticipate working with faculty across MSK Departments to design the future of cancer care and to transform how we deliver it using innovative technologies and study designs. I expect to focus intensively on recruitment, mentorship, and team building. I plan to continue to seek extramural funding to support this work and intend to spearhead preparation of a T32 grant submission to support training opportunities in cancer care delivery for MSK faculty.

Research Support:

Current Research Funding

2022-2027	<p>MATCHES: Making Telehealth Delivery of Cancer Care at Home Effective and Safe (Admin Core)</p> <p>Total Award Amount (including Indirect Costs): \$1,655,260</p>
	National Institute of Health 1 P50 CA271357-01
	Co-Investigator (PIs: Morris, M./ Panageas, K./Stetson, P.)
	<p>The COVID-19 pandemic forced explosive growth of telehealth—synchronous virtual visits between patients and clinicians—under crisis conditions, but it is now essential to generate robust evidence regarding when telehealth’s benefits outweigh its risks in oncology practice; how to ensure that telehealth provides highly effective, efficient, and equitable care; and how to identify best practices for telehealth implementation. The MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center will bring together investigators and trainees from multiple disciplines to meet these challenges by 1) conducting pragmatic and pilot trials across our integrated network of outpatient oncology practices; 2) leveraging our substantial cache of observational data to build the evidence base necessary to establish best practices for telehealth-supported cancer care; and 3) to investigate concerns about safety and addressing the risk of exacerbating disparities in access to high quality healthcare. Our</p>

	Center's theme focuses on developing data science methods to integrate telehealth data with other complex data streams to measure outcomes and quality of care.
2021-2022	Optimizing the Treatment of Pancreatic Adenocarcinoma Total Award Amount (including Indirect Costs): \$21,317
	National Cancer Institute R01CA212086
	Co-Investigator (PI: Hur, C.)
	The purpose of this study is to improve both individual patient survival and population mortality linked to pancreatic ductal adenocarcinoma through the development of a mathematical modeling platform.
2021-2023	A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors Total Award Amount (including Indirect Costs): \$45,928
	National Cancer Institute U01CA246648
	Co-Investigator (PI: Partridge, A./Naughton, M.)
	The overall goals of this study are to: 1) To determine the efficacy of the YES intervention, a web-based symptom monitoring and self-management tool, compared to usual care in improving quality of life (QOL), as measured by the Quality of Life in Adult Cancer Survivors (QLACS) at 6-months (primary outcome) in adolescent and young adult breast cancer survivors (AYA BC). 2) To determine the efficacy of the YES intervention compared to usual care in reducing AYA BC concerns and symptoms at 6-months; 3) To determine the sustainability of the effects of YES on AYA concerns and symptoms, and QOL at 9 months post-baseline, after the completion of the 6-month active intervention period.
2020-2025	Comparative Modeling of Effective Policies for Colorectal Cancer Control Total Award Amount (including Indirect Costs): \$6,159,670
	National Cancer Institute U01 CA253913
	Co-Investigator (PIs: Zuber, A. / Knudsen, A./ Kuntz, K./ Lansdorp-Vogelaar, I./ Rutter, C.)
	Despite large increases in screening in the past two decades, colorectal cancer remains the second leading cause of cancer death in the United States. Our research has shown that 60% of these deaths could be prevented by better use of available screening interventions. In this proposal, we use microsimulation modeling to evaluate and help prioritize interventions to further reduce the burden of colorectal cancer.
2018-2023	SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice

	Total Award Amount (including Indirect Costs): \$137,788
	National Cancer Institute UM1CA233080
	Co-PI (Hassett, M./Osaroghian, R./Schrag, D./Wong, S.)
	SIMPRO's overarching goal is to develop, implement, and evaluate a multi-component ePRO reporting and management system to improve symptom control for patients recovering from cancer surgery or patients receiving palliative chemotherapy in small, rural, and community cancer centers.
2013-current	The PROSPECT Trial
	Total Award Amount: N/A
	Alliance for Clinical Trials Oncology
	PI
	This national cooperative group clinical trial (Alliance) randomized 1194 patients with locally advanced rectal cancer to receive or not receive pelvic radiation as part of curative intent treatment. The study includes patient-reported outcomes, quality of life assessment, economic assessment, molecular and imaging markers. I have served as the overall PI of this national trial. Follow up is ongoing.

Past (Completed) Funding

1999-2004	Genetic Predisposition Testing in Colorectal Cancer
	NCI / K07 Mentored Training Award in Cancer Prevention
	PI
	The specific aims are: 1) To determine the significance of inherited 1307K Adenomatous polyposis coli (APC) mutations in a hospital-based cohort of Ashkenazi Jews with colorectal cancer and with adenomatous polyps; 2) To assess effectiveness, measured in life-years and quality-adjusted life years, and the cost-effectiveness, of genetic testing for inherited colorectal cancer susceptibility.
2004-2007	Reasons for Adjuvant Therapy Decisions in Colorectal Cancer
	American Cancer Society
	PI
	This study evaluates the reasons that vulnerable patients in a New York City Hospital-based cohort do or do not initiate, and complete postoperative adjuvant chemotherapy following a diagnosis of colorectal cancer and evaluates mechanisms that are associated with high quality cancer care.
2004-2007	Diffusion of Chemotherapy Innovations
	NCI / R21 CA2198353
	PI

	The specific aims are: 1) To describe how new chemotherapeutic strategies disseminate into oncology practice using the SEER-Medicare linked data; and 2) To measure the extent to which specific chemotherapy regimens are identifiable from the billing claims submitted to Medicare and the payment vouchers received.
2005-2007	Cost-Effectiveness of Gemcitabine/Bevacizumab versus Gemcitabine/Placebo
	NCI Companion to CALGB Protocol 80303
	PI The aim of this study is to use primary clinical trial data on effectiveness and health care utilization for patients with pancreas cancer as well as primary quality of life data to estimate the incremental cost-effectiveness of the addition of bevacizumab to gemcitabine.
2005-2009	The Roots of Health Disparities: The Quality of Primary Care
	National Institute of Aging (NIA) / R01AG025687
	Co-Investigator
	This proposal evaluates the reasons underlying the prevalence of racial disparities in health outcomes for patients with chronic diseases using linkages between the Community Tracking Study survey of physicians and Medicare claims data.
2006-2007	Development of Prognostic Models in Colorectal Cancer
	American Joint Commission on Cancer
	PI
2006-2008	Tracking Disease Outcomes in Specialty Cancer Centers: The Colorectal Cancer Database
	NCCN
	PI
	The aims of this study are to measure adherence to NCCN clinical practice guidelines and to evaluate quality of colorectal cancer treatment.
2006-2008	Access to Prescription Drug Coverage for Patients Enrolled in Therapeutic Cancer Clinical Trials
	NCI Companion to CALGB Protocol 80405
	This is a survey embedded in the context of a clinical trial whose aim is to identify the strategies patients adopt to cope with the high costs of cancer treatment and related medications for symptom control.
	PI
2006-2009	Access to Mammography Facilities and Use of Screening by African American Women Foundation
	Susan Komen Foundation
	Co-PI
	This study is to determine the region-specific capacity to perform screening mammography and to understand systems level barriers to screening for African American compared to non-minority women.

2007-2010	Modeling Effective Health Policies for Colorectal Cancer
	NCI / U01CA097426
	Co-Investigator
	The MISCAN-Colon model is used to estimate the absolute and relative contribution of changing lifestyle factors, screening, and improved therapy on the observed trends in CRC incidence and mortality in the United States 1975-2002. Then the model is used to explore future scenarios to evaluate the potential impact of current and newly developing technologies on lifestyle interventions, chemoprevention, screening, and treatment improvement on future trends in CRC incidence and mortality in the US. The study also translates the impact of implementation of effective interventions on reducing the burden of CRC with respect to life years gained, quality of life, required medical capacity and economic burden.
2007-2010	A Population Based Policy Model for Colorectal Cancer
	NCI / U01CA088204
	Co-Investigator
	To characterize treatment patterns, outcomes and costs for chemotherapy and surgical interventions for patients with colorectal cancer.
2008-2010	Augmenting NY Cancer Registry Data to Assess Breast and Colorectal Cancer Care
	Association of Schools of Public Health (ASPH)/Center for Disease Control (CDC) / S3888
	Co-Investigator
	To develop 1) Technical reports describing the linkage steps themselves; 2) methodological reports characterizing the yield from the data source; and 3) research papers describing cancer care delivery to Medicaid recipients in these two large states (NY and CA).
2008-2010	The Cancer Multi-Center Research Consortium Coordinating Center (CAN-DECIDE Consortium)
	Agency for Healthcare Research and Quality (AHRQ) Health and Human Services Agency (HHS) / 290200500161
	Co-Investigator
	The goals of the project are to evaluate the real-world effectiveness of chemotherapy treatments for CRC using data from a variety of non-experimental sources and examine both survival outcomes and the incidence of serious treatment complications such as hospitalization, heart attacks and strokes.
2008-2010	Development of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
	NCI HHSN / 261200800043C
	Co-Investigator
	The overall goal of this project is to create a mechanism for patient self-reporting of adverse symptom events in cancer treatment trials called the PRO-CTCAE, consisting of an integrated item bank and electronic platform that is validated, reliable, sensitive, generalizable, feasible, accepted by clinicians and regulators, and interoperable with NCI and industry databases and adheres to established data standards.

2008-2012	Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium II
	NIH/NCI 3U01CA093344
	Co-Investigator (PI: Harrington, D.)
	The major goal of this project is to leverage the data and research from the prior research project by studying patients who survived beyond 15 months to assess several key domains that could not be addressed in CanCORS I. These include: outcomes and quality of care among survivors; dissemination of new, targeted cancer therapies; outcomes and quality of care among patients with recurrent advanced disease; and finally, the association of care processes and disease-related outcomes in the community setting. This proposal evaluates various statistical methods used to analyze studies of the association between case volume and clinical outcome. The primary data sets for these analyses are derived from Surveillance, Epidemiology and End Results (SEER)-Medicare and Dr. Schrag contributes her expertise related to the primary construction of these cohorts and their clinical interpretation
2009-2015	Cancer Care Delivery in Medicaid
	NCI / R01 CA131847
	PI
	This proposal seeks to identify how access to safety net health insurance and race/ethnicity intersect with common cancer diagnoses. We will evaluate care patterns for Medicaid patients and, where data permit, compare them to patterns for otherwise similar persons not covered by Medicaid. Specifically, for each important aspect of cancer care we will also measure racial/ethnic disparities within the Medicaid program.
2009-2012	Building CER Capacity: Aligning Cancer Research Networks, Centers for Medicare & Medicaid Services (CMS), and State Resources to Map Cancer Care
	NIH / UC2CA148185
	Co-Investigator
	Through a partnership between investigators in the Cancer Research Network and DF/HCC, we propose to develop a resource with sufficient depth and breadth to support high quality cancer comparative effectiveness research addressing two keys gaps: treatment of advanced disease and population-based research of patterns and outcomes of cancer care in patients not represented in SEER-Medicare.
2010-2012	BWH/DFCI: CAN-DEcIDE-2 Coordinating Center
	AHRQ / HHSA290201000006I
	PI
	The CAN-DEcIDE (CAN=Cancer, DEcIDE=Developing Evidence to Inform Decisions about Effectiveness) Consortium was established in 2008 in response to an AHRQ request for proposals. I was awarded this contract serves as the founding PI. This project portfolio conducts stakeholder driven comparative effectiveness research across the spectrum of malignant disease. CAN-DEcIDE's portfolio evaluates the real-world effectiveness of and health outcomes of cancer treatment and surveillance using both observational and experimental study designs. Development of infrastructure and resources to build capacity to answer stakeholder driven questions is also a priority.

2010-2012	U Mass Boston / DFHCC U54 Partnership
	NIH / 1U54 CA156732
	Co-Investigator
	This project develops a comprehensive partnership between the University of Massachusetts Boston (UMB) and the Dana-Farber/Harvard Cancer Center (DF/HCC). The goal of the partnership is to address health disparities in minority populations; to improve research in basic, clinical, and population science; and to provide training, research, and outreach opportunities for minority students, nurses, and scientists.
2010-2013	Quality, Disparities and Breast Cancer Care in Medicaid
	Susan G. Komen for the Cure / Career Catalyst in Disparities Research (CC-DR) Grant
	Co-Investigator
	The objectives of this project are to evaluate the quality of care offered to minority and economically disadvantaged women with breast cancer, to compare performance relative to measures of breast cancer care quality across different racial/ethnic and economic status groups, to identify predictors of poor-quality care, and to generate policy and practice-ready solutions that can be used to improve cancer care quality within the next 3-5 years.
2010-2013	Comparing the Long-Term and Real-World Effectiveness of Initial Management Strategies for ductal carcinoma in situ (DCIS)
	AHRQ / HHS290200500161
	Co-Investigator
	The aims of this study are to systematically evaluate the outcomes for women with DCIS who select alternative treatment strategies. Information from two large cohort studies with rich clinical detail will be incorporated into a simulation model that will explicitly and systematically compare outcomes of alternative management strategies. This information will be used to design patient centered tools that frame the tradeoffs of alternative treatment choices in order to inform decision making.
2010-2015	Black-White Differences in Advanced Cancer Communication, Acceptance, and Care
	NIH/NCI R01CA10637005-A1
	Co-Investigator
	The goal of this project is to apply the Structural Influence Model (SIM) of Health Communication to examine whether black-white disparities in communication processes (e.g., prognostic disclosures) and communication goals (e.g., acceptance of illness) mediate racial disparities in end-of-life (EOL) care, rates of treatment goal attainment (i.e., receipt of care consistent with patient preferences), and quality of life at the EOL.
2010-2015	Lung Cancer Disparities Center: Jointly Addressing Race & Socioeconomic Status
	NIH / 1P50CA148596-01
	Co-Investigator (PI: Williams, D.)
2010-2015	Modeling Effective Health Policies for Colorectal Cancer

	NIH / U01CA152959-01)
	Co-Investigator
	The goals of the project are to provide population-based answers to health policy questions of how to evaluate or implement programs of risk reduction, cancer screening, or treatment to affect CRC incidence and mortality over time.
	The Center leadership envisions establishing a premier and permanent center for research focused on lung cancer disparities.
2010-2015	Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
	NCI / HHSN26120100063C
	Co-Investigator and Site PI
	The goals of the project a collaboration with PI E. Basch MD, University of North Carolina my K07 mentee are to create a mechanism for patient self-reporting of adverse symptom events in cancer treatment trials called the PRO-CTCAE, consisting of an integrated item bank and electronic platform that is validated, reliable, sensitive, generalizable, feasible, accepted by clinicians and regulators, and interoperable with NCI and industry databases and adheres to established data standards.
2012-2016	Cancer and Leukemia Group B CCOP Research Base
	CALGB/ U10CA037447
	Co-Investigator
2012-2015	Explaining variations in Intensity of EOL Care
	NIH/ R01CA164021
	Co-Investigator (PI: Keating, N.)
	CanCORS data supplemented with medical record data and physician survey data linked with administrative data from Medicare, private health plans, Medicaid, and the VA to examine the intensity of EOL care and expenditures among nearly 4000 patients with advanced lung or colorectal cancer. Hierarchical models will assess the patient, physician, hospital, and area factors influencing intensity of EOL care.
2012-2018	Partnerships Between Medicaid, Tumor Registries & Cancer Control Researchers
	NIH/KO5 CA169384
	PI
	The goals of the project are to expand Capacity for Tumor Registry-Medicaid-Medicare Data Linkages to Evaluate Cancer Care, evaluate the Quality and Effectiveness of Care for Medicaid Recipients with Cancer, and identify Specific Mechanisms that Explain Shortcomings and Design Interventions to Improve Care. The goal is to train the next

	generation of cancer control researchers and to collaborate with Medicaid program leadership to strategically optimize care delivery for program enrollees.
2013-2015	The Cost of Cancer Care in California
	California Healthcare Foundation/No Grant Number
	PI
	This project evaluated the costs and value of cancer care delivery to Californians across categories of race, ethnicity, socioeconomic position, and comorbidity. It was used by the governor and health commissioner to target strategies to improve cancer care across the state.
2013-2017	Post-treatment Surveillance in Breast Cancer
	PCORI/CE-1304-6543
	Co-Investigator (PI: Greenberg, C.)
	We seek to develop a new approach to surveillance following breast cancer treatment which will be more patient-centered and effective than the existing one-size-fits-all approach and will consider individual risk factors.
2013-2017	CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems
	NIH: U24CA171524
	Co-Investigator (PI: Kushi, L.)
2013-2018	Improving the Informed Consent Process for Palliative Chemotherapy
	PCORI/CE-1304-6517
	PI
	The major goal of this project is to develop a library of written and video informed consent tools for 5 metastatic colorectal cancer chemotherapy regimens. The toolkit will then be tested to determine if it improves the quality of informed consent for palliative chemotherapy, cancer patients' treatment decisions, engagement in advanced care planning and health outcomes. The tools will be amenable to broad dissemination via patient-accessible cancer education websites and oncology clinics.
2013-2018	Clustered Semi-Competing Risks Analysis in Quality of End-of-Life Care Studies
	NIH

	Co-Investigator (PI: Haneuse, S.)
	The major goal of the project conducted with Sebastian Haneuse PhD, a biostatistician at the T.H. Chan Harvard School of Public Health is to develop new statistical methods and software and provide new epidemiological results for quality of end-of-life cancer care in the US. The methods will be broadly applicable to all advanced health conditions, beyond cancer, such as Alzheimer's disease, many of which directly affect large segments of an increasingly aging US population.
2013-2018	Statistical Informatics for Cancer Research
	NIH/NCI/P01CA134294
	Co-Investigator (PI: Lin, X./Dominici, F.)
	This program project tackled a series of problems motivated by the analysis of high dimensional data arising in population-based studies of cancer.
2015-2019	Esophageal Adenocarcinoma Screening, Treatment and Prevention
	NCI/R01CA140574
	Co-Investigator (PI: Hur, C.)
	The goal of this proposal is to identify strategies that reduce EAC morbidity and mortality by using a simulation model to systematically evaluate the population-level impact of alternative EAC prevention, screening and treatment strategies.
2016-2020	Specialized Center - Cooperative Agreements EL CENTRO: Engaging Latinos in the CENTER of Cancer TReatment Options
	NIH/NCI: U54CA156732
	Co-Investigator (PI: Viswanath, V.)
	The objective of the study is to improve the quality of advanced cancer care and treatment decision making for Latinos with advanced GI cancer.
2017-2019	Building sustainable and innovative research in Cancer and Cardiovascular disease: Planning the design and development of the South American Center of Research Excellence to Counter Non communicable diseases.
	NIH/NCI P20 CA217231
	Multi-PI (PI: Irazola, V./Schrag, D.)
	The goal of this proposal is to develop the South American Center of Research Excellence in Chronic Non-communicable diseases to establish research programs and capacity

	building activities related to cancer and cardiovascular diseases prevention and control in South America
2017-2019	Dana-Farber/Harvard Cancer Center Administrative Supplement - AACR Project GENIE and the NCI: Powering Precision Medicine in Pediatric Cancer Patients
	NIH 3P30 CA006516-53S4
	Co-Investigator (Overall PI: Glimcher, L. / Project PI: Janeway, K.)
	The focus of this project is to retrieve prior treatment history, clinicopathologic, and outcomes data associated with approximately 650 of the sequenced tumors deposited in the GENIE Registry from pediatric patients treated at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. This aggregation of clinical-grade pediatric sequencing and regulatory-grade clinical data elements will address a limiting factor in the full realization of precision oncology in pediatric populations, which is insufficient numbers of patients.
2018-2020	PCF Challenge Award
	Prostate Cancer Foundation
	Co-Investigator (PI: Pomerantz, M.)
	The Impact of DNA Damage Repair Abnormalities in Prostate Cancer Aim 1. To determine the association between pathogenic variants in DDR genes in the germline-genome and long-term risk of lethal PC in 3,000 men with high-risk, localized PC. Aim 2. To estimate incremental effectiveness, cost-effectiveness and cost-utility ratios for DDR germline mutation screening and risk-tailored management compared to no screening and standard management for men with, or at risk for, high-grade/locally advanced PC.
2020-2021	PCF Challenge Award
	Prostate Cancer Foundation
	Co-Investigator (PI: Van Allen, Eli)
	A genomics-guided clinical interpretation and translational discovery engine for prostate cancer

2020-2023	Academic Career Skills for Junior Faculty Researchers
	NIH/NCI: UE5 CA246746
	Co-Investigator (PI: Pirl)
	The three-day workshop on research career skills to address the NASDC goal of helping NCI-funded junior faculty to “maintain long-term productivity in their research careers.” The workshop will enhance skills in leadership, mentoring, and collaborating as well as managing the social and emotional challenges of research.

2019-2024	Precision Management of Cystic Precursors to Pancreatic Cancer
	NIH: R01CA237133
	Co-Investigator (PI: Pandharipande, P.V.)
	The purpose of this proposal is to optimize the management of incidentally detected cystic precursors of pancreatic cancer through the development of a mathematical modeling platform.
2019-2024	Covid-19-related cervical cancer treatment interruption and role of neoadjuvant chemotherapy
	NIH: R01CA236546
	Co-Investigator (PI: Dryden-Peterson)
	A multilevel intervention (Potlako+) to improve cancer detection and treatment initiation The aim of this project is to develop, implement, and evaluate a multi-level intervention to improve cancer early diagnosis.
2016-2022	Effectiveness Trial (CANVAS Trial, AFT-28)
	PCORI CER-1503-29805
	PI
	The major goals of this grant are to, Aim 1: To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with solid tumor malignancies. Aim 2: To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months. Aim 3: To compare the impact of DOAC vs. LMWH/warfarin therapy on the experience and burden of anticoagulation therapy for cancer patients with VTE. Aim 4: To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE.

N. MENTORING

Current Mentees*

*Research mentees only

Name	Christopher Lathan, MD, MS, MPH
Site/Position	Medical Director, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Faculty Director for Cancer Care Equity Physician, Assistant Professor of Medicine, Harvard Medical School (JCO 2016)
Expected Period	2015- current
Project/Accomplishments	1 st author manuscript in JCO, faculty recruits, new positions in organization
Goals/expected Outcomes	Advance equity, diversity and inclusion in research and faculty development at DFCI
Type of Supervision	Research mentorship, Career and leadership mentorship- appointed Chief Diversity Equity and Inclusion Officer at DFCI in 2021

Name	Nadine Jackson McCleary
Site/Position	Assistant Professor in Medicine, Dana-Farber Cancer Institute
Expected Period	2017-current
Project/Accomplishments	Mentored on Donahue Foundation award.
Goals/expected Outcomes	Dr. McCleary is a medical oncologist focused on cancer informatics and integrating systematic ascertainment of social determinants of health data to mitigate health disparities and improve care quality.
Type of Supervision	Research and career guidance Mentor on multiple foundation awards (Donahue 2019-2021)

Name	Matthew Mossanen, MD
Site/Position	Assistant Professor of Urology, Brigham and Women's Hospital
Expected Period	2017- current
Project/Accomplishments	Project: Comparative effectiveness research in prostate cancer and prehabilitation to improve outcomes of cystectomy.
Goals/expected Outcomes	Mentor on K23 submission (not yet awarded) and multiple manuscripts and protocols
Type of Supervision	Research

Name	Charlotta Lindvall, MD
Site/Position	Physician, Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Instructor, Harvard Medical School.
Expected Period	2018- current
Project/Accomplishments	Projects: application of machine learning and artificial intelligence methods to improve cancer patient symptom control and quality of life.
Goals/expected Outcomes	First R01 award, multiple first authored manuscripts
Type of Supervision	Research mentorship in health services research

Name	Irbaz Riaz MD
Site/Position	Visiting Research Fellow from Mayo Clinic, Rochester MN
Expected Period)	2020-current
Project/Accomplishments	Project: Genomic-phenomic data linkages to improve care for prostate cancer. (Co-mentor with Eli Van Allen).
Goals/expected Outcomes	Two first authored manuscripts
Type of Supervision	Research training in health services research

Name	Eleni Stavrou MD
------	------------------

Site/Position	2 nd year Medical Oncology Fellow, Dana-Farber-Mass General Fellowship program
Expected Period	2020-current
Project/Accomplishments	Project: Evaluating patients and clinicians' preferences for telehealth beyond the pandemic: A pilot trial among women with early-stage breast cancer.
Goals/expected Outcomes	Execution of a telehealth-focused research protocol and 3 manuscripts
Type of Supervision	Research training in health services research funded on T32

Name	Sun Young Kim, MD
Site/Position	Associate Professor of Medicine (Gastrointestinal Medical Oncology) from Seoul, South Korea.
Expected Period	2020-current
Project/Accomplishments	Project: Optimizing quality of life for patients with rectal cancer. Health Ministry of South Korea.
Goals/expected Outcomes	Two first authored manuscripts
Type of Supervision	Research training in health services research

Name	Catherine Marinac PhD
Site/Position	Instructor in Medicine (Cancer Epidemiology and Control) Dana Farber Cancer Institute.
Expected Period	2020-current
Project/Accomplishments	Project: Cancer screening using blood-based assays: challenges to implementation and opportunities to address disparities. Protocol sponsored by Grail
Goals/expected Outcomes	3 1 st authored manuscripts on cancer-focused population sciences,
Type of Supervision	Research training in cancer-focused population sciences-K99 award mentor (K99 award received 2020)

Name	David Merola
Site/Position	Candidate for PhD in Epidemiology, Harvard Chan School of Public Health.
Expected Period	2020-current
Project/Accomplishments	Project: Simulation of the Paloma trial from observational data and advancing methods for leveraging observational data to evaluate cancer treatment outcomes.
Goals/expected Outcomes	Receipt of doctoral degree and publication of thesis in peer reviewed journal
Type of Supervision	Co-mentor with Dr. Sebastian Schneeweiss on doctoral thesis.

Name	Ottavia Zattra
Site/Position	Candidate for MD at Harvard Medical School
Expected Period	2020-current

Project/Accomplishments	Project: Factors predisposing patients with cancer to get COVID-19 and to recover from COVID-19. I serve as the primary mentor for this medical student's yearlong research project conducted during the height of the pandemic.
Goals/expected Outcomes	Publication of project as first author manuscript
Type of Supervision	Research

Name	Andrea Enzinger MD MPH
Site/Position	Assistant Professor of Medicine, Harvard Medical School and medical oncologist, DFCI
Expected Period	2011-2021
Project/Accomplishments	Projects: Multiple projects related to advancing symptom control and end of life care. Primary mentor on K07 award, advisor on first R21 (both awarded) and R01 in preparation. Multiple 1 st author publications.
Goals/expected Outcomes	Transition to independence from K mentee via R01 funding
Type of Supervision	Research

Name	Jennifer Cracchiolo
Site/Position	Memorial Sloan Kettering Cancer Center/Assistant Attending, Surgery
Expected Period	2022-present
Project/Accomplishments	
Goals/expected Outcomes	
Type of Supervision	Research

Name	Angela Green
Site/Position	Memorial Sloan Kettering Cancer Center/Assistant Attending (L1), Medicine
Expected Period	2022-present
Project/Accomplishments	
Goals/expected Outcomes	
Type of Supervision	Research

Name	Robert Daly (Secondary Mentor)
Site/Position	Memorial Sloan Kettering Cancer Center/ Assistant Attending, Medicine
Expected Period	2022-present
Project/Accomplishments	
Goals/expected Outcomes	
Type of Supervision	Research

Past Mentees*

**This list is restricted to research mentees with whom I had significant sustained multi-year interactions. Clinical mentees and individuals with whom mentoring relationships are episodic or primarily in a co-pilot role are not listed.*

<i>Name</i>	Larissa Temple, MD
<i>Site/Position</i>	Health Services Research Fellow; (J Clin Oncol 2004; Dis Colon Rectum 2005; Ann Surg 2009)
<i>Mentoring Period</i>	2003-2007
<i>Project/Accomplishments</i>	2 research manuscripts, receipt of foundation funding
<i>Current Position</i>	Chair Colorectal Surgery, University of Rochester.
<i>Type of Supervision</i>	Research

<i>Name</i>	Elena Elkin PhD
<i>Site/Position</i>	Professor of Health Policy and Epidemiology
<i>Mentoring Period</i>	2002-2007
<i>Project/Accomplishments</i>	4 research manuscripts, primary mentor on her K07 award
<i>Current Position</i>	Professor Health Policy, Columbia University Medical School
<i>Type of Supervision</i>	Research

<i>Name</i>	Thomas Jang, MD
<i>Site/Position</i>	Health Services Research Fellow; 1 publication (Arch Intern Med 2010)
<i>Mentoring Period</i>	2006-2007
<i>Project/Accomplishments</i>	N/A
<i>Current Position</i>	Assistant Professor of Surgery, Robert Wood Johnson Medical School, Piscataway Township, NJ
<i>Type of Supervision</i>	Research

<i>Name</i>	David Sher, MD, MPH
<i>Site/Position</i>	Harvard Medical School Mentorship; (Int J Radiat Oncol Biol Phys. 2011; J Clin Oncol 2011)
<i>Mentoring Period</i>	2008-2011
<i>Project/Accomplishments</i>	2 publications
<i>Current Position</i>	Professor and Chief of Head and Neck Radiation Oncology, University of Texas Southwestern
<i>Type of Supervision</i>	Research

<i>Name</i>	Caprice Greenberg MD MPH
<i>Site/Position</i>	Center for Outcomes and Policy Research Dana-Farber
<i>Mentoring Period</i>	2008-2012
<i>Project/Accomplishments</i>	3 publications, 1 PCORI award

<i>Current Position</i>	Professor and Chief of Surgery, Medical University of South Carolina
<i>Type of Supervision</i>	<i>Research</i>

<i>Name</i>	Rachel Yung, MD
<i>Site/Position</i>	3 rd Year Medical Oncology Fellow, (Oncologist 2011, JNCI 2012)
<i>Mentoring Period</i>	2010-2012
<i>Project/Accomplishments</i>	1 st authored paper in JNCI
<i>Current Position</i>	Associate Professor at the Fred Hutchinson Cancer Center
<i>Type of Supervision</i>	<i>Research</i>

<i>Name</i>	Dhruv Sharma, PhD
<i>Site/Position</i>	Mentorship, (JAMA 2012)
<i>Mentoring Period</i>	2011-2013
<i>Project/Accomplishments**</i> ,	2 nd authored paper in JAMA
<i>Current Position</i>	Associate Professor of Biostatistics, Michigan State University
<i>Type of Supervision</i>	<i>Research</i>

<i>Name</i>	Junya Zhu, PhD
<i>Site/Position</i>	Mentorship (JAMA 2012, Cancer 2013)
<i>Mentoring Period</i>	2011-2013
<i>Project/Accomplishments**</i> ,	1 st authored manuscript in JAMA
<i>Current Position</i>	Assistant Professor, Johns Hopkins School of Medicine
<i>Type of Supervision</i>	<i>Research</i>

<i>Name</i>	Gabriel Brooks, MD
<i>Site/Position</i>	Regional variation in Medicare spending and survival among older adults with advanced cancer. (JNCI 2013, Health Affairs 2014. JCO 2016) ASCO Career Development Award Primary Mentor
<i>Mentoring Period</i>	2011-2016
<i>Project/Accomplishments</i>	Primary mentor on ASCO Career Development Award 2015
<i>Current Position</i>	Assistant Professor of Medicine, Dartmouth Hitchcock Medical School
<i>Type of Supervision</i>	<i>N/A</i>

<i>Name</i>	John Withington MD
<i>Site/Position</i>	Physician and Harkness Fellow, Division of Population Sciences.
<i>Mentoring Period</i>	2019
<i>Project/Accomplishments</i>	White Paper: differences in cancer policy between the US and the UK. Commonwealth Fellowship.
<i>Current Position</i>	Urologist, National Health Service, United Kingdom
<i>Type of Supervision</i>	<i>Research</i>

Institutional Training Grants and Mentored Trainee Grants*

**In addition to the trainees noted in the table below, I have served as a co-mentor or an advisor on training grants and awards to over 50 medical oncology, pediatric oncology, radiation oncology, general internal medicine and surgery fellows as well as to postdoctoral research fellows with PhDs in health services, biostatistics, epidemiology and health economics. Their names and projects are not listed. In 2020 I serve as a co-mentee on 2 K07, 5 K08 and 5 K23/K24 and 2 K99 NIH training awards as well as other institutional Ks (K12s), as well as AACR and ASCO Career Development awards and a variety of smaller foundation awards.*

<i>Award Source:</i>	Primary mentorship on K07 and co-I on R01 (JNCI 2011, JCO 2014, Annals of Internal Medicine 2014, Cancer 2016)
<i>Project title:</i>	Strategies to optimize cancer care delivery for patients undergoing stem cell transplant.
<i>Duration of support:</i>	2008-current
<i>Mentee</i>	Michael Hassett, MD, MPH

<i>Award Source: (funding agency, type of grant)</i>	K99 and Doris Duke award.
<i>Project title:</i>	Building a data model to evaluate clinical outcomes in oncology. Machine learning to accelerate phenomic curation for precision medicine. K99 award and Doris Duke award.
<i>Duration of support:</i>	2016-current
<i>Mentee</i>	Ken Kehl, MD, MPH

<i>Award Source:</i>	ASCO Young Investigator Award & K08 Application submitted in 2021.
<i>Project title:</i>	Young Investigator awarded: The effects of white bagging versus buy and bill on cancer care quality and spending and Cancer Control in incarcerated populations. K08: submitted: Cancer control in incarcerated persons and parolees in the criminal justice system.
<i>Duration of support:</i>	2020-current
<i>Mentee</i>	Christopher Manz, MD, MSc

<i>Award Source:</i>	Serve co-mentor with Dr. David Leaf, a nephrologist on Dr. Gupta's K23 career development award (received May 2021)
----------------------	---

<i>Project title:</i>	Preventing deterioration of renal function in patients with cancer.
<i>Duration of support:</i>	2021-current
<i>Mentee:</i>	Shruti Gupta, MD, MPH

<i>Award Source:</i>	<i>K07 Award from NCI NCI</i>
<i>Project title:</i>	<i>Building a validated system to elicit patient-reported outcomes suitable for regulatory-grade decision making</i>
<i>Duration of support:</i>	<i>2003-2009</i>
<i>Mentee:</i>	Ethan Basch, MD

<i>Award Source: (funding agency, type of grant)</i>	<i>K07 Award from NCI</i>
<i>Project title:</i>	<i>Treatment decisions in Ductal Carcinoma in Situ</i>
<i>Duration of support:</i>	2004-2008
<i>Mentee:</i>	<i>Elena Elkin, PhD</i>

<i>Award Source: (funding agency, type of grant)</i>	<i>K07 Award from NCI</i>
<i>Project title:</i>	<i>Comparative effectiveness of treatment for Hepatocellular Cancer</i>
<i>Duration of support:</i>	<i>2008-2012</i>
<i>Mentee (if applicable):</i>	<i>Hanna Sanoff, MD</i>
<i>Award Source:</i>	<i>K07 Award from NCI</i>
<i>Project title:</i>	<i>A gastric cancer prevention policy model (Gut 2014)</i>
<i>Duration of support:</i>	<i>2013-2016</i>
<i>Mentee (if applicable):</i>	Jennifer Yeh, ScD

<i>Award Source:</i>	T32 fellowship and K23 awarded June 2021.
<i>Project title:</i>	Strategies to optimize cancer care delivery for patients undergoing stem cell transplant.
<i>Duration of support:</i>	2019-2021
<i>Mentee:</i>	Ashely Nelson, PhD

O. INSTITUTIONAL LEADERSHIP ACTIVITIES

<i>Role(s)/Position</i>	<i>Institution/Location</i>	<i>Dates</i>
Chair, Committee on Creation of Institutional and Clinical Data for Research	Memorial Sloan-Kettering Cancer Center New York, NY	2002-2006
Deputy Associate Director, Population Sciences	Dana-Farber / Harvard Cancer Center (DF/HCC), Boston, MA	2008-2017
Steering Committee	Dana-Farber / Harvard Cancer Center (DF/HCC), Boston, MA	2011-2017
Chair, Clinical Data Governance	Dana-Farber Cancer Institute, Boston MA	2011-2017
Chair, Avoidable Hospitalizations Committee	Dana-Farber Cancer Institute, Boston, MA	2013-2016
Chair, Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) Quality Improvement Committee	Dana-Farber Cancer Institute, Boston, MA	2013-2019
Co-Chair, Clinical Operations and Research Information System (CORIS)	Dana-Farber Cancer Institute, Boston, MA	2013-
Chief, Division of Population Sciences and the McGraw Patterson Center for Population Sciences	Dana-Farber Cancer Institute, Boston, MA	2013-2021
Founding Chair, Cancer Care Delivery Research Program of the Dana-Farber Harvard Cancer Center	Dana-Farber Cancer Institute, Boston, MA	2014-2021
Member, Committee on Promotions and Appointments	Dana-Farber Cancer Institute, Boston, MA	2014-2017
Co-Chair, Committee on Promotions and Appointments (with Dr. Todd Golub)	Dana-Farber Cancer Institute, Boston, MA	2018-2021
Chair, Search for Chief Research Information Officer	Dana-Farber Cancer Institute, Boston, MA	2015
Chair, Ad Hoc Search Committee for Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Cancer Center	Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA	2016

Chair of three ad hoc committees for Professorial promotion	Harvard Medical School	2015-2020
PI, Training in Oncology Focused Population Sciences (NCI-funded T32)	Dana-Farber / Harvard Cancer Center (DF/HCC), Boston, MA	2017-2021
George J. Bosl Chair at Memorial Sloan Kettering Cancer Center	Memorial Sloan Kettering Cancer Center, New York, NY	2022-present

P. INSTITUTIONAL ADMINISTRATIVE ACTIVITIES

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
Search Committee for Physician-in-Chief	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2002
Department of Medicine, Quality Assurance Committee	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2006
Internal Funding Award Review Committees for Outcomes Research	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2007
Department of Medicine, Fellowship Selection Committee	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2003-2007
Quality Metrics Committee	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2005-2007
Search for Chair of Breast Surgery	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2006-2007
Scientific Progress Review Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2008-2015
Search for Chair of Nursing Research	Member	Dana-Farber Cancer Institute, Boston, MA	2008-2009
Committee on Status of Women Faculty	Member	Dana-Farber Cancer Institute, Boston, MA	2008-2012

DF/HCC Gastrointestinal Cancer Program Leadership Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2009-2011
Dean's Committee on Research of Comparative Effectiveness	Member	Harvard Medical School, Boston, MA	2010-2012
Residency Selection Committee	Member	Brigham and Women's Hospital, Boston, MA	2010-2015
Search Committee for Chair of Medical Oncology Fellowship Program	Member	Dana-Farber Cancer Institute, Boston, MA	2011-2012
Women's Senior Faculty Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2010-2012
Strategic Planning Clinical Research Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2015
International Physician Advisory Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2014
Research Computing Planning	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2015
Steering Committee for NIH Training Grant: Program in Cancer Outcomes Research Training (PCORT)	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2017
Partners eCare Research Council	Member	Partners Healthcare, Boston, MA	2013-
Search Committee for Ethics Faculty	Member	Dana-Farber Cancer Institute, Boston, MA	2013
Executive Committee for Clinical Research	Member	Dana-Farber Cancer Institute, Boston, MA	2013-

Member, Executive Committee for Clinical Research	Member	Dana-Farber Cancer Institute, Boston, MA	2013-
Search Committee for Professor and Chair of the Department of Psychosocial Oncology and Palliative Care (POPC)	Member	Dana-Farber Cancer Institute, Boston, MA	2013
International Medical Services Advisory Committee	Member	Brigham and Women's Hospital, Boston, MA	2011-2014
Casty Award Selection Committee	Member	Brigham and Women's Hospital, Boston, MA	2013-
Search Committee for Chair of Medicine, Cambridge Health Alliance	Member	Beth Israel Deaconess Medical Center and Harvard Medical School Dana-Farber Cancer Institute, Boston, MA	2015-2016
Ad Hoc Promotion Committee for 5 faculty	Member	Harvard Medical School, Harvard Chan School of Public Health, Boston, MA	2015-2018
Search Committee for President and CEO	Member	Dana-Farber Cancer Institute, Boston, MA	2015
Ad Hoc Review Committee for Proposed Appointment of faculty in Departments of Surgery (3), Radiology (1) Palliative care (2), Pathology (1) Informatics (2), Radiation Oncology (1)	Member	Brigham and Women's Hospital, Harvard Medical School, Boston, MA	2015

Ad Hoc Search Committee for Vice-Chair for Psychosocial Oncology and Palliative Care	Member	Dana-Farber Cancer Institute, Boston, MA	2016
Search Committee for Chair of the Department of Biostatistics and Computational Biology at DFCI and Professor of Biostatistics at the Harvard Chan School	Member	Dana-Farber Cancer Institute, Harvard Chan School of Public Health, Boston, MA	2016
Women's Wellness Oversight Committee	Member	Brigham and Women's Hospital, Boston, MA	2017-2020
Ad Hoc Search Committee for Professor of Medicine at Harvard Medical School and Chief of the Gastroenterology at Massachusetts General Hospital	Member	Massachusetts General Hospital, Boston, MA	2018
Massachusetts Cancer Registry Advisory Committee Steering Committee	Member	The Commonwealth of Massachusetts, Department of Public Health	2017-2021
Faculty Search Committee for Cancer Energetics	Member	Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA	2018
Faculty Search Committee for Health Informatics/Machine Learning	Member	Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA	2018
Faculty Well-Being	Member	Dana-Farber Cancer Institute,	2018-

		Brigham and Women's Hospital, Harvard Medical School, Boston, MA	
Faculty Diversity and Inclusion	Member	Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA	2019-
Cantor Center Steering Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2019
Ad Hoc Search Committee for a Professor at Harvard Medical School who will serve as Director of the Cancer Center	Member	Beth Israel Deaconess Medical Center, Boston, MA	2020-2021
Search Review Committee for the Barbara E Engelhardt, PhD, Associate Professor, Computer Science Department	Member	Princeton University, Princeton, NJ	2021
MHCCAP	Member	Memorial Sloan Kettering Cancer Center, New York, NY	2021-current
COAP	Member	Memorial Sloan Kettering Cancer Center, New York, NY	2022-current

Q. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Leadership in Extramural Organizations

<i>Role</i>	<i>Organization</i>	<i>Dates</i>
Co-Chair Cancer Control and Health Outcomes	Cancer and Leukemia Group B (CALGB), Chicago, IL	2004-2009
Chair, Colorectal Cancer (CRC) Database	National Comprehensive Cancer Network (NCCN), Fort Washington, PA	2005-2008
Elected Member, Board of Directors	American Board of Internal Medicine (ABIM), Philadelphia, PA	2007-2012

Elected Member, Board of Directors	American Society of Clinical Oncology	2008-2012
Executive Committee	Cancer and Leukemia Group B (CALGB), Chicago, IL	2008-2013
Chair, Colorectal Cancer Committee	National Comprehensive Cancer Network, Fort Washington, PA	2008-2013
Associate Editor, JNCI	Journal of the National Cancer Institute	2012-2014
Member, National Cancer Policy Forum Planning Committee member and co- chair for 5 workshops	Institute of Medicine, Washington DC	2014-2020
Associate Editor, JAMA	Journal of the American Medical Association, Chicago, IL	2014-
Member	Rectal-Anal Cancer Task Force, NCI Cancer Treatment and Evaluation Program	2015-
Member	Board of Trustees, Alliance for Clinical Trials in Oncology, Chicago, IL	2016-2020
Co-Chair	American Association of Cancer Research's Project GENIE: Biopharma Consortium	2018-
Co-Chair Cancer Control and Health Outcomes	Cancer and Leukemia Group B (CALGB), Chicago, IL	2004-2009
Chair, Colorectal Cancer (CRC) Database	National Comprehensive Cancer Network (NCCN), Fort Washington, PA	2005-2008

Regional

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
Search Committee for Physician-in-Chief	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2002
Junior Faculty Council	Co-Chair	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2003

Department of Medicine, Quality Assurance Committee	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2006
Internal Funding Award Review Committees for Outcomes Research	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2007
Department of Medicine, Fellowship Selection Committee	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2003-2007
Quality Metrics Committee	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2005-2007
Search for Chair of Breast Surgery	Member	Memorial Sloan-Kettering Cancer Center, New York, NY	2006-2007
Scientific Progress Review Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2008-2015
Search for Chair of Nursing Research	Member	Dana-Farber Cancer Institute, Boston, MA	2008-2009
Committee on Status of Women Faculty	Member	Dana-Farber Cancer Institute, Boston, MA	2008-2012
DF/HCC Gastrointestinal Cancer Program Leadership Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2009-2011
Dean's Committee on Research of Comparative Effectiveness	Member	Harvard Medical School, Boston, MA	2010-2012
Residency Selection Committee	Member	Brigham and Women's Hospital, Boston, MA	2010-2015
Search Committee for Chair of Medical Oncology Fellowship Program	Member	Dana-Farber Cancer Institute, Boston, MA	2011-2012
Women's Senior Faculty Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2010-2012

Strategic Planning Clinical Research Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2015
International Physician Advisory Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2014
Research Computing Planning	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2015
Steering Committee for NIH Training Grant: Program in Cancer Outcomes Research Training (PCORT)	Member	Dana-Farber Cancer Institute, Boston, MA	2012-2017
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) Quality Improvement Committee	Chair	Dana-Farber Cancer Institute, Boston, MA	2013-2019
Clinical Operations and Research Information System (CORIS)	Co-Chair	Dana-Farber Cancer Institute, Boston, MA	2013-2020
Avoidable Hospitalizations Committee	Chair	Dana-Farber Cancer Institute, Boston, MA	2013-2016
Partners eCare Research Council	Member	Partners Healthcare, Boston, MA	2013-2018
Search Committee for Ethics Faculty	Member	Dana-Farber Cancer Institute, Boston, MA	2013
Executive Committee for Clinical Research	Member	Dana-Farber Cancer Institute, Boston, MA	2013-2021
Member, Executive Committee for Clinical Research	Member	Dana-Farber Cancer Institute, Boston, MA	2013-2021
Search Committee for Professor and Chair of the Department of Psychosocial Oncology	Member	Dana-Farber Cancer Institute, Boston, MA	2013

and Palliative Care (POPC)			
International Medical Services Advisory Committee	Member	Brigham and Women's Hospital, Boston, MA	2011-2014
Casty Award Selection Committee	Member	Brigham and Women's Hospital, Boston, MA	2013-2020
Search Committee for Chair of Medicine, Cambridge Health Alliance	Member	Beth Israel Deaconess Medical Center and Harvard Medical School Dana-Farber Cancer Institute, Boston, MA	2015-2016
Ad Hoc Promotion Committee for 5 faculty	Member	Harvard Medical School, Harvard Chan School of Public Health, Boston, MA	2015-2018
Search Committee for President and CEO	Member	Dana-Farber Cancer Institute, Boston, MA	2015
Ad Hoc Review Committee for Proposed Appointment of faculty in Departments of Surgery (3), Radiology (1) Palliative care (2), Pathology (1) Informatics (2), Radiation Oncology (1)	Member	Brigham and Women's Hospital, Harvard Medical School, Boston, MA	2015
Ad Hoc Search Committee for Vice-Chair for Psychosocial Oncology and Palliative Care	Member	Dana-Farber Cancer Institute, Boston, MA	2016
Search Committee for Chair of the Department of Biostatistics and Computational Biology at DFCI and Professor	Member	Dana-Farber Cancer Institute, Harvard Chan School of Public Health, Boston, MA	2016

of Biostatistics at the Harvard Chan School			
Ad Hoc Search Committee for Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Cancer Center	Chair	Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA	2016
Women's Wellness Oversight Committee	Member	Brigham and Women's Hospital, Boston, MA	2017-2020
Ad Hoc Search Committee for Professor of Medicine at Harvard Medical School and Chief of the Gastroenterology at Massachusetts General Hospital	Member	Massachusetts General Hospital, Boston, MA	2018
Massachusetts Cancer Registry Advisory Committee Steering Committee	Member	The Commonwealth of Massachusetts, Department of Public Health	2017-2021
Faculty Search Committee for Cancer Energetics	Member	Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA	2018
Faculty Search Committee for Health Informatics/Machine Learning	Member	Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA	2018
Faculty Well-Being	Member	Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA	2018-2020
Faculty Diversity and Inclusion	Member	Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA	2019-2020
Cantor Center Steering Committee	Member	Dana-Farber Cancer Institute, Boston, MA	2019

Ad Hoc Search Committee for a Professor at Harvard Medical School who will serve as Director of the Cancer Center	Member	Beth Israel Deaconess Medical Center, Boston, MA	2020-2021
Search Review Committee for the Barbara E Engelhardt, PhD, Associate Professor, Computer Science Department	Member	Princeton University, Princeton, NJ	2021

National

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
Clinical Economics Core	Member	Cancer and Leukemia Group B	1999-2005
Cancer Control and Health Outcomes	Member, Vice Chair	Cancer and Leukemia Group B	2002-2007
Health Services Committee	Cadre Member	Cancer and Leukemia Group B	2003-2008
Panel on Cancer Care Quality	Member	Institute of Medicine, Washington, DC	2004-2006
Colorectal Cancer Panel	Member	National Quality Forum, Washington, DC	2004-2007
Outcomes Database Steering Committee	Member	National Comprehensive Cancer Network, Fort Washington, PA	2004-2013
Quality Metrics Committee	Member	NCCN-American Society of Clinical Oncology (ASCO), Alexandria, VA	2005-2006
Medicare Coverage Advisory Committee (MCAC)	Member	Center for Medicare and Medicaid Services, Baltimore, MD	2005-2008
Cancer Survivorship Panel	Member	Institute of Medicine	2006-2007
Advisory Board	Member	Cancer Research Network (CRN), Bethesda, MD	2006-2011

Advisory Panel on Surveillance	Member	National Cancer Institute (NCI), Bethesda, MD	2007
Comparative Effectiveness Research (CER) Working Group	Member	Cancer and Leukemia Group B	2010
Comparative Effectiveness Research Working Group	Chair	Alliance for Clinical Trials in Oncology	2010-2012
Search Committee for New PI for the CRN	Member	Cancer Research Network, Bethesda, MD	2011
Scientific Review Committee for the Cancer Research Network	Member	National Cancer Institute	2011
Strategic Planning Committee for Combined Cooperative Group	Member	CALGB- North Central Cancer Treatment Group (NCCTG)- American College of Surgeons Oncology Group (ACOSOG)	2011
Colorectal Cancer Clinical Trials Planning Workshop	Member	National Cancer Institute	2011
NCI Directors' Provocative Questions Workshop— Behavioral, Population, Epidemiology, and Prevention	Member	National Cancer Institute	2011
Special Awards Selection Committee	Member	American Society of Clinical Oncology (ASCO)	2012-2015
Health Policy Task Force	Member	American Association for Cancer Research (AACR)	2012-2021
Defining High Value Cancer Care	Participant/speaker in symposium	Institute of Medicine	2013
Provocative Questions Workshop	Participant	National Cancer Institute (NCI) Bethesda, MD	2013

Charles A. King Trust Clinical and Health Services Research Committee	Member	The Medical Foundation	2013-2019
National Cancer Policy Forum Planning Committee, Workshop on Patient Access to Cancer Drugs	Member	Institute of Medicine	2014
External Advisory Board	Member	University of North Carolina Cancer Center	2014-
External Advisory Board Member	Member	Tisch Cancer Institute, Mount Sinai, NY	2015-
Oncology Drugs Advisory Committee	Member	Food and Drug Administration, Washington DC	2015, 2017, 2018
Advisor to California Health Policy Commission	Member	California State Legislature, Sacramento, CA	2015-2018
External Advisory Board, Institute for Cancer Outcomes	Member	University of Alabama Comprehensive Cancer Center, Birmingham, AL	2016-2018
Rectal Anal Task Force	Member	Cancer Treatment and Evaluation Program, National Cancer Institute	2017-
National Center for Health Statistics Committee on the future of Population-Based Surveys	Member	National Center for Health Statistics, Washington, DC	2017-2018
Board of Trustees, Alliance for Clinical Trials in Oncology Foundation	Member	The Alliance for Clinical Trials in Oncology	2017-2020
Scientific Advisory Committee	Member	Value in Cancer Care Consortium	2017-2020

Massachusetts Health Policy Commission	Member	Payment Reform in Oncology	2018-2021
External Advisory Board	Member	The Lymphoma Epidemiology Outcomes (LEO) Cohort Study (P01)	2019-2020
Assistant Secretary of Health and Human Services for Planning and Evaluation for Chronic Care Delivery	Advisor	HHS, Washington, DC	2019-2020
Center for Medicare and Medicaid Services	Advisor	Next generation oncology performance, Washington, DC	2018-2020
Committee on Implications of Discarded Weight-Based Drugs	Member	National Academies of Sciences, Engineering, and Medicine's (The National Academies)	2019-2021
Modernizing Staging Algorithms	Member	American Association of Cancer Research	2020
Colorectal Cancer Alliance's Medical Scientific Advisory Committee (MSAC)	Member	Colorectal Cancer Alliance	2020

International

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
Strategies and Standards for Delivery of Colorectal Cancer Treatment	Advisor	National Health Services, United Kingdom	2004-2006
Strategic Planning for Cancer Care Quality	Consultant	Swedish Health Ministry	2008-2011
EHR Data and Cancer Care Delivery	Advisor	Kupat Cholim, Israel Health Insurance, Tel Aviv, Israel	2014-2016
Cancer Care Quality Evaluation	Advisor	French Ministry of Health, Paris France	2015-2017

Cancer Care Delivery and Reimbursement Policy, Ministry of Health	Advisor	Ministry of Health, Jerusalem, Israel	2015
Strategic Initiatives in Cancer Population Science	Advisor	Cancer Research United Kingdom, London, UK	2016-2017
External Advisory Board, Cancer Care Ontario	Member	Ontario Institute for Cancer Research, Toronto, Ontario	2017-

Grant Reviewing/Study Sections

<i>Role(s)</i>	<i>Organization Name</i>	<i>Dates</i>
Study Section for Program Projects in Population Sciences	National Cancer Institute, Rockville, MD Ad Hoc Reviewer	2002
Survivorship Awards Review Committee	Memorial Sloan-Kettering Cancer Center, New York, NY Member	2003-2006
Review Committee for Boyer Awards	Memorial Sloan-Kettering Cancer Center, New York, NY Member	2005-2007
Health Services Study Section	National Institute of Health, Bethesda, MD Ad Hoc Member (5 times)	2005-2008
Catalyst Program, Grant Review Committee	Dana-Farber Cancer Institute, Boston, MA Member	2008-2009
Study Section Special Emphasis Panel for Review of Applications to Foster Systems of Care Coordination	National Institute of Health Bethesda, MD Member	2008
Special Emphasis Panel to review Complex Patients and Comparative Effectiveness Research	Agency for Healthcare Research and Quality, Bethesda, MD Member	2010
Special Emphasis Panel in Population Sciences: Building New Clinical Infrastructure for Comparative Effectiveness Research	Agency for Healthcare Research and Quality, Bethesda, MD Member	2010

U54 Grant Application Review Committee	University of Massachusetts Boston–Dana-Farber/Harvard Cancer Center, Boston, MA Member	2010-2016
Health Services Organization and Delivery	National Institutes of Health, Center for Scientific Review Bethesda, MD Permanent Member	2013-2018
Comparative Effectiveness Research	Patient Centered Outcomes Research Institute, Washington, DC. Ad hoc reviewer	2015-2017
Cancer Care Delivery Research	KWF-Dutch Cancer Society, Amsterdam, Netherlands Ad hoc reviewer	2016
Cancer Care Quality and Control	National Health Service, London, United Kingdom Ad hoc reviewer	2017
Health Services Research-Exception Panel	National Institutes of Health, Center for Scientific Review Co-Chair, Bethesda, MD Member	2019-2021
Review Board for the New York Polyethnic-1000 project	New York Genome Center, New York, NY Chair of Study Section	2020
Grant Reviewer for Ministry of Health Cancer Control Portfolio	Government of Germany, Ministry of Health	2021

Editorial Activities

Journal Reviewing/ad hoc reviewing

<i>Journal / Organization Name</i>	<i>Dates</i>
New England Journal of Medicine (NEJM) Reviewed 3 or more articles per year in last 6 years	2013-
Journal of the American Medical Association (JAMA) (Associate Editor)	2013-
JAMA Oncology	2013-
JAMA Internal Medicine	2013-
Journal of the National Cancer Institute (JNCI)	2013-
Journal of Clinical Oncology (JCO)	2013-

Journal of Oncology Practice	2013-
Medical Care	2013-
Cancer	2013-
Annals of Internal Medicine	2013-
Health Services Research	2013-
Health Affairs	2013-
Lancet Oncology	2013-
The Oncologist	2013-
Health Economics	2013-
The Journal of General Internal Medicine	2013-
Clinical Cancer Research	2013-
Cancer Discovery	2013-

Editorial Board Membership

<i>Board / Organization Name</i>	<i>Dates</i>
Editorial Board Member	Journal of Clinical Oncology 2001-2004
Editorial Board Member	Journal of Clinical Oncology 2006-2009
Editorial Board Member	Journal of Clinical Oncology 2015-2020
Editorial Board Member	Journal of the National Comprehensive Cancer Network 2006-2020
Consultant	Analysis of Senate Bill 961 2010
Associate Editor	The Journal of National Comprehensive Cancer Network 2010-2014
Editorial Board Member	Gastrointestinal Cancer Research 2012-2017
Associate Editor	Journal of the National Cancer Institute 2012-2014
Associate Editor	Journal of the International Society of Gastrointestinal Oncology 2013-2016
Associate Editor	Journal of the American Medical Association (JAMA) 2014-

Editorial Board Member	Journal of Clinical Oncology	2019-2021
------------------------	------------------------------	-----------

R. INVITED AND/OR PEER-SELECTED PRESENTATIONS

Local

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
The Impact of Hospital Procedure Volume on Outcomes Following Colon Cancer Surgery/Grand Rounds	Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY	2000
The Evidence for Volume Outcome Relationships in Cancer Surgery: Is it Robust Enough to Influence Policy? /Grand Rounds	Weill-Cornell Medical College, New York, NY	2001
Using Administrative Data for Evaluating Quality of Cancer Care/Grand Rounds	Department of Public Health, Weill-Cornell Medical College, New York, NY	2002
What We Know About the Quality of Care for Patients with Colorectal Cancer/Grand Rounds	Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY	2003
Adjuvant Treatment Decision-Making for Patients with Stage II Colon Cancer/Grand Rounds	Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY	2004
Measuring the Quality of Cancer Care/Grand Rounds	Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY	2006
Overview of Pay for Performance Initiatives/Grand Rounds	Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY	2006
Comparative Effectiveness and Oncology Research Priorities/Grand Rounds	Division of Medicine, Massachusetts General Hospital, Boston, MA	2009
Cancer Care Delivery in Medicaid/Seminar	Center for Outcome and Policy Research, Dana-Farber Cancer Institute, Boston, MA	2009
The Ethics of Incorporating Cost Considerations into Therapeutic Encounters in the Context of Advanced Cancer/Lecture Department of Ethics	Harvard Medical School, Boston, MA	2009
Coordinating Care: Who Is Going to Do It and How? /Symposium	Partners Health Care's Connected Health Symposium, Boston, MA	2009

Disparities in Cancer Survival for the Medicaid Insured/Center for Outcomes and Policy Research Conference, Division of Population Sciences, Dana Farber Cancer Institute	Dana-Farber/Partners Cancer Center(DF/PCC) Gastrointestinal Cancer Center (GCC) Symposium, Boston, MA	2010
Breast Cancer Care for Women Insured by Medicaid/Seminar	Dana-Farber Cancer Institute, Boston, MA	2010
The Next Frontier in the War on Cancer: Economics/Symposium, The War on Cancer 40 Years Later	HMS Faculty Symposium, Harvard Medical School, Boston, MA	2010
Comparative Effectiveness Research, Clinical Investigator Series	Dana-Farber Cancer Institute, Boston, MA	2011-2012
Preoperative radiation or selective preoperative radiation and evaluation before chemotherapy and TME (PROSPECT) Rectal Cancer Study,	Dana-Farber Cancer Center, South Weymouth, MA	2012
Evaluating the Quality and Outcomes of Care for Medicaid Insured Women with Breast Cancer, Breast Rounds	Massachusetts General Hospital, Boston, MA	2013
Oral Abstract Session: Plenary Abstracts, ASCO Quality Care Symposium	Boston, MA	2014
Survivorship Research: Challenges and Opportunities, Cancer Survivorship: Optimizing Care and Outcomes, CME Course	Dana-Farber Cancer Institute, Boston, MA	2014
Integrating Patient Reported Outcomes into Efficacy and Effectiveness Research, Population Sciences Research Program	Dana-Farber Cancer Institute, Boston, MA	2015
Impact of ACA Reform on Cancer Screening Treatment and Prevention, Health Policy Conference and Alumni Symposium	Joseph Martin Center, Boston, MA	2015
Global Economics of Cancer Development and Population Impact Panel	Partners Healthcare World Medical Innovation Forum, Westin Copley Place, Boston, MA	2016
Integrating Patient Reported Outcomes (PROs) into Cancer Research and Clinical Care Patient-centered Comparative Effectiveness Research Center (PCERC),	Brigham and Women's Hospital, Boston, MA	2016
The GENIE Consortium and leveraging our investment in Precision Medicine, Department of Medical Oncology	Dana-Farber Cancer Institute, Boston, MA	2018
PROs in Oncology: Past Present and Future Opportunities	Brigham and Women's Hospital Department of Medicine Boston, MA	2018

Life of a Clinical Trial: From a Good Idea to Recommending to Patients	Colorectal Cancer Alliance/DF/BWCCC Conference, Newton, MA	2019
Cancer Care Delivery Research using the Electronic Health Record HMS Clinical Informatics Symposium	Harvard Medical School Informatics Symposium	2020
Opportunities and Pitfalls of Cancer Screening using Blood-Based Assays-DF/HCC Symposium	Dana Farber Harvard Cancer Center Population Sciences (virtually due to pandemic)	2020
Genomic-Phenomic Linkages to increase implementation of precision medicine- Harvard Chan School of Public Health Workshop	Harvard School of Public Health Symposium (virtually due to pandemic)	2020
Division of Philanthropy All Staff Meeting, Dana-Farber Cancer Institute	Dana-Farber Cancer Institute (virtually due to pandemic)	2021
Department of Medicine Grand Rounds: Recovery, Re-visioning, and Resilience: Department of Medicine Priorities moving beyond the COVID-19 Pandemic	Memorial Sloan Kettering Cancer Center (virtually due to pandemic)	2021
ASTRO 2021 Annual Meeting, Presidential Symposium: Digital Health to Improve Patient Outcomes and Experience	Virtual Due to Pandemic	2021

Regional

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
Evaluating Patterns of Cancer Care Using SEER-Medicare/Monthly Research Seminar	Cancer Center of the Columbia University, New York, NY	1999
Patterns of Care Among Patients with Colorectal Cancer: Insights from SEER-Medicare/Seminar	N/A	2000
Using Decision Analysis to Inform Clinical Trial Design/Grand Rounds	University of Medicine and Dentistry, Robert Wood Johnson Medical School, Piscataway, NJ	2000
Integrating the Results of Decision Analyses into Clinical Practice: A Roadmap/Seminar	International Center for Health Outcomes and Innovation Research (INCHOIR) Research Group: Columbia University	2001

	College of Physicians and Surgeons, New York, NY	
Do We Deliver What Works? Adjuvant Treatment for Patients with Stage III Colon Cancer/Grand Rounds	Department of Medicine, Mt. Sinai Hospital, New York, NY	2002
Cancer Registries and Improving Cancer Care Delivery/Grand Rounds	NYU Department of Medicine, New York, NY	2002
The High Cost of Targeted Cancer Chemotherapy: Strategies for Discussing Benefits and Risks with Patients/Bi-annual meeting	New York Cancer Society, NYU Cancer Center, New York, NY	2003
Quality of Care for Colorectal Cancer/Seminar	New York City Department of Public Health, New York, NY	2003
Dissemination of New Chemotherapy Treatments/Seminar	Department of Medicine, Mt. Sinai Medical School, New York, NY	2005
Strategies to Improve the Quality of US Cancer Care/Seminar	Chemotherapy Foundation Symposium, New York, NY	2005
What We Do and Don't Know About Geriatric Oncology/Grand Rounds	10 Community hospitals, New York, NY	2007
Racial, Ethnic, and Socioeconomic Disparities in US Cancer Care and Strategies to Overcome Them/Grand Rounds	10 Community hospitals, New York, NY	2007
Linking Public Health Data Systems to Improve Cancer Care Delivery/Seminar	New York State Department of Health, Albany, NY	2007
Patient and Physician Attitudes Towards the Escalating Costs of Cancer Treatment/Roundtable	Therapeutic Insight Industry-Academia-Government Roundtable, New York, NY	2008
Visiting MD/Tumor Board	St. Luke's Hospital, New Bedford, MA	2009
Coping with High Cost Treatments: Patient, Provider and Policy Perspectives/Grand Rounds	Medical Ethics Rounds, Lahey Clinic, Burlington, MA	2009

From Efficacy to Effectiveness: A Work Example/Workshop	The Politics and Practice of Comparative Effectiveness Research Workshop, Radcliffe Institute for Advanced Study, Cambridge, MA	2010
A Balancing Act: Comparative Effectiveness vs. Efficacy and the Cancer Research Agenda/Lecture	Breast Cancer: New Horizons, Current Controversies, Hope for the Future lecture, Boston, MA	2010
Interview on Study of Cancer among patients with advanced disease	Journal Watch Audio General Medicine, Wayland, MA	2010
Selective Use of Radiation in Rectal Cancer, 36 th Annual Alumni Conference	MSKCC, New York, NY	2011
Speaker & Panelist: Real-World Personalized Medicine: Examining the Role of Real-World Evidence in Personalizing Health Care	Personalized Medicine Conference, Cambridge, MA	2017
Leveraging “Real World Data” to Accelerate Progress in Cancer Medicine: Opportunities and Obstacles.	CRCS Seminar, Cambridge, MA	2017
Harvard University Data Sciences Workshop Inaugural Conference: Speaker and panelist: Data Science to Improve Cancer Care	N/A	2018
ASCO Quality Care Symposium	Boston Marriott Copley Place, Boston, MA	2021
Harvard Business School: Biotech & Clinical Trials at Home	Harvard Business School, Boston, MA (virtually due to pandemic)	2022

National

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
Medical Decision Making for Carriers of BRCA1 and BRCA2 Mutations/Seminar	National Institute of Health Women’s Health Initiative Research Meeting, Santa Fe, NM	1998

Cancer Prevention Oral Presentation/Annual Meeting	American Society of Clinical Oncology, Los Angeles, CA	1999
Determinants of High-Quality Care Among Medicare Patients with Colorectal Cancer – A Claims Based Approach/Seminar	Robert Wood Johnson Clinical Scholars Program, University of Chicago, Chicago, IL	2000
Gleaning Information About Hospital Characteristics using American Hospital Association (AHA) and Hospitals Cost Reports Information System (HCRIS) Data/Seminar	SEER-Medicare Investigators Meeting, National Cancer Institute, Bethesda, MD	2000
Understanding Volume-Outcomes Relationships, Strengths, and Limitations of Existing Analyses/Cancer Symposium	Centers for Disease Control, Atlanta, GA	2000
Health Service Research Oral Presentation Session/Annual Meeting	American Society of Clinical Oncology, San Francisco, CA	2001
Disentangling the Role of Hospital and Surgeon as Determinants of Outcomes Center Following Cancer Surgery/Seminar	Cancer Prevention Series, MD Anderson Cancer Center, Houston, TX	2001
Explaining Trends in Colorectal Cancer Mortality/Investigators Meeting	Cancer Intervention and Surveillance Modeling Network (CISNET), National Cancer Institute, Washington, DC	2001
Population-based Resources for Measuring the Quality of US Cancer Care/Group Meeting	Cancer and Leukemia Group B, Chicago, IL	2001
Population-based Resources for Evaluating Cancer Care/Seminar	Department of Medicine, University of Miami, Miami, FL	2002
Health Services Research Oral Abstracts/Annual Meeting	American Society of Clinical Oncology, Orlando, FL	2002
Educational Session: Health Services Research Careers in Cancer/Annual Meeting	American Society of Clinical Oncology, Orlando, FL	2002

Access to Prescription Drugs for Cancer Patients/Group Meeting	Cancer and Leukemia Group B, Chicago, IL	2003
Health Services Research Oral Presentations/Research Discussion, Annual Meeting	American Society of Clinical Oncology, Chicago, IL	2003
Using Administrative Data Sources to Evaluate the Quality of US Cancer Care/Grand Rounds	Massey Cancer Center, Virginia Commonwealth University, Richmond, VA	2004
Patient Navigation and the Quality of Three US Cancer Care/Annual Meeting	Presidential Symposium, American Society of Clinical Oncology, New Orleans, LA	2005
Cancer Treatment for Elderly Patients, Understanding the Difference Between Clinical Trials and Real-World Practice Patterns/Seminar	BJ Kennedy-Paul Carbone Memorial Symposium on Geriatric Oncology, National Cancer Institute, Washington, DC	2005
Using Decision Aids to Facilitate Adjuvant Treatment Decision Making/Seminar	5th Annual Perspectives in Colorectal Cancer Symposium, Chicago, IL	2005
Patterns of Post-Treatment Surveillance for Patients with Colon Cancer/Seminar	Joint Symposium on Cancer Survivorship, Institute of Medicine, Washington, DC	2005
Using Population-based Data Sources to Evaluate How Clinical Trial Results are Incorporated into Oncology Practice/Seminar	Indiana University Cancer Center, Indianapolis, IN	2005
Integrating Progress in Colorectal Cancer Chemotherapy into Practice/Annual Meeting	Hoosier Group Oncology, Indianapolis, IN	2005
The SEER-Medicare Linked Data and Other Population-based Approaches to Measuring the Quality of US Cancer Care/Seminar	National Cancer Advisory Board, Washington, DC	2005
Strategies and Pitfalls Associated with Linking Pay to Performance in Oncology/Seminar	United Health Care Advisory Board, Chicago, IL	2005
Integrating Health Services Research into Clinical Trial Design/Retreat	American Society of Clinical Oncology	2005

	Leadership, Washington, DC	
Integrating Health Services Research into Clinical Trial Design/Grand Rounds	Division of Oncology, University of Chicago, Chicago, IL	2005
Strategies for Improving the Quality of US Cancer Care/Seminar	Meeting for Congress and Congressional Aides and Alliance of Dedicated Cancer Centers, Washington, DC	2005
Mary Mulready Sullivan Oncology Symposium: Defining, Measuring and Paying for High Quality Cancer Care/Grand Rounds	Department of Medicine, Hartford Hospital, Hartford, CT	2006
Implementing Cancer Survivorship Care Planning/Workshop	Institute of Medicine, Washington, DC	2006
How to Write a "Survivorship Prescription," The Oncology Treatment Summary and Survivorship Care Plan/Annual Meeting	Education Session, American Society of Clinical Oncology, Atlanta, GA	2006
Economic Consequences of Better Cancer Chemotherapy/Seminar	50th Anniversary Meeting, Cancer and Leukemia Group B, Chicago, IL	2006
Medicare Physician Payment: How to Build a Payment System that Provides Quality, Efficient Care for Medicare Beneficiaries/Testimony	United States Congress Energy and Commerce Committee, Washington, DC	2006
Opportunities for Linking Federal Data to Prioritize Health Needs of the Nation/Seminar	Department of Health and Human Services Symposium on Improving Health Services Research through Linkages, Washington, DC	2006
Data Sources for Measuring Quality of Care in the Era of Personalized Medicine/Seminar	Workshop on Strategies to Improve Cancer Care Delivery, National Cancer Institute, Bethesda, MD	2006

Pay for Performance and Quality of Care Initiatives/Grand Rounds	University of Massachusetts Lewin Symposium, Department of Medicine, Springfield, MA	2006
What Drives Adoption of New Chemotherapy Drugs in Oncology?	Association of Health Care Economics Special Symposium on Drug Discovery in the Era of Biological Therapy, Washington, DC	2007
Evaluating the Quality and Outcomes of Care Using Cancer Registry and Claims Data/Seminar	All Ireland Healthcare Joint Meeting, National Cancer Institute, Bethesda, MD	2007
Colorectal Cancer Abstracts/Discussant of Research Poster Presentations/Annual Meeting	American Society of Clinical Oncology, Chicago, IL	2007
The Pay for Performance Movement and How it Does and Does Not Foster the Quality of US Cancer Care/Grand Rounds	Midland Hospital, Midland, MI	2007
Data Do and Do Not Help Answer this Common Question/Annual Meeting	American Society of Clinical Oncology, Chicago, IL	2007
The Economics of US Cancer Care and Its Implications for Care Quality/Seminar	Symposium on the Quality of Cancer Care, Midland, MI	2007
Imagining Better Delivery Systems for Cancer/Seminar	Aspen Institute for Ideas, Aspen, CO	2007
The Rationale for Treatment Summaries in Cancer Care/Annual Meeting	American Society of Clinical Oncology, Chicago, IL	2007
Program on Cancer Outcomes Research Training Fellows: Developing Systems to Engage Patients in Reporting Symptoms During Cancer Treatment/Grand Rounds	Massachusetts General Hospital, Boston, MA	2007
Abstracts in Colorectal Cancer Poster Discussion Session/Annual Meeting	American Society of Clinical Oncology, Chicago, IL	2008

What We Can and Should Learn from the Erythropoiesis-Stimulating Agent (ESA) Story/Annual Meeting	Education Session, American Society of Clinical Oncology, Chicago, IL	2008
Can We Do Less Instead of More? Simplifying Therapy for Locally Advanced Rectal Cancer/Seminar	MD Anderson Cancer Center, Houston, TX	2008
Taking Stock of the Quality of Care Movement in Oncology/Grand Rounds	Division of Medical Oncology, Case Western University Hospital, Cleveland, OH	2008
Building Comparative Effectiveness Research Capacity in Cancer/Presentation	The Agency for Health Care Research and Quality, Washington, DC	2008
Reshaping Systems to Optimize Cancer Quality Care/Seminar	Brookings Institute, Washington, DC	2009
New Paradigms in Rectal Cancer Treatment/Seminar	Division of Gastroenterology, MD Anderson Cancer Center, Houston, TX	2009
Economics of Cancer Chemotherapy/Grand Rounds	Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX	2009
Comparative Effectiveness Research: What It Is and What Does It Mean for Oncology Practice? /Annual Meeting	Extended Education Session, American Society of Clinical Oncology, Orlando, FL	2009
Strategies for Maintaining Board Certification in Medical Oncology/Annual Meeting	Education Session, American Society of Clinical Oncology, Orlando, FL	2009
Strategies for Coping with Prescription Drug Costs for Clinical Trial Participants/Annual Meeting	Clinical Science Symposium, American Society of Clinical Oncology, Orlando, FL	2009

Incorporating Financial Considerations into Oncology Decision Making: Challenges and Opportunities/Annual Meeting	Education Session, American Society of Clinical Oncology, Orlando, FL	2009
Building Comparative Effectiveness Research Capacity/Symposium	Lung Cancer Research Foundation, New York, NY	2009
The Effectiveness of Cancer Care Delivery for Indigent Patients in New York State/Grand Rounds	Memorial Sloan-Kettering Cancer Center, New York, NY	2009
Insuring and ensuring high quality cancer care for our most vulnerable patients/Grand Rounds	University of Michigan Comprehensive Cancer Center, Ann Arbor, MI	2009
Neoadjuvant FOLFOX-bev without radiation for locally advanced rectal cancer/Symposium	GI Symposium, American Society of Clinical Oncology, Orlando, FL	2010
Cancer Care Delivery in Medicaid/Grand Rounds	Endowed Visiting Professor, Moments in Leadership, Louisiana State University Health Sciences Center, New Orleans, LA	2010
Closing the Implementation Gap/Oncology Grand Rounds	Winship Cancer Center, Emory University, Atlanta, GA	2010
Partnering with Medicaid to Enhance CER in Cancer/Conference	California Cancer Registry Scientific Conference, Sacramento, CA	2010
Implementing the PRO-CTCAE system in the context of cooperative group trials/Meeting	Development of the PRO-CTCAE Meeting, National Cancer Institute, Bethesda, MD	2010
Strategies for Communicating the Costs and Benefits of Medical Interventions/Annual Meeting	Education Session, American Society of Clinical Oncology, Chicago, IL	2010
Neo-adjuvant FOLFOX-bevacizumab, with selective use of radiation, for locally advanced rectal cancer/Annual Meeting	Education Session, American Society of	2010

	Clinical Oncology, Chicago, IL	
Developing platforms for comparative effectiveness research on survivorship care	NCI Evaluation Survival Care, Washington, DC	2011
Streamlining Rectal Cancer Therapy	ASCO Gastrointestinal Cancer Symposium, San Francisco, CA	2011
Adjuvant and Neoadjuvant Chemotherapy for Resectable Rectal Cancer	Society of Surgical Oncology Rectal Symposium, San Antonio, TX	2011
The comparative effectiveness of chemotherapy for colorectal cancer/Visiting Professor	Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC	2011
Analytic Methods in Comparative Effectiveness Research, Seminar with Postdoctoral Fellows	Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC.	2011
Priority Setting in Comparative Effectiveness Research	AHRQ DEcIDE Cancer Consortium Stakeholder Meeting, Rockville, MD	2011
Importance/Value of Standardized Treatment Algorithms: what has been accomplished in oncology?	American College of Rheumatology (ACR) Clinical Research Conference, Chicago, IL	2011
The Past, Present and Future of Comparative Effectiveness Research in Oncology	John Hopkins Bloomberg School of Public Health, Baltimore, MD	2011
Comparative Effectiveness Research	National Press Club with JAMA Editors, Washington, DC	2012
Integrating Effectiveness Research into the Cooperative Group Research Portfolio	Community Clinical Oncology Program (CCOP), Bethesda, MD	2012
Measuring and Incentivizing Value in Cancer Chemotherapy	Institute of Medicine Workshop on Costs of	2012

	Cancer Care, Washington, DC	
From Efficacy to Effectiveness: Strategies for Increasing Accrual to Important Clinical Trials	Georgetown University Medical School, Ruesch Center Symposium, Washington, DC	2012
Preoperative Chemotherapy Alone and the PROSPECT Trial	ASCO Gastrointestinal Cancer Symposium, San Francisco, CA	2013
Anal and Rectal Carcinomas	Great Debates & Updates in GI Malignancies, New York, NY	2013
Gastric and GE Junction Adenocarcinomas	Great Debates & Updates in GI Malignancies, New York, NY	2013
Faculty Panel: Great Debates & Updates in GI Malignancies	New York, NY	2013
Raising the Bar: Can We Diminish the Impact of Race, Age, and Expertise as Factors in Patient Outcome	Education Session, ASCO, Chicago, IL	2013
The National Cancer Institute's Patient Reported Outcomes-PRO-CTCAE	ASCO Annual Meeting Chicago, IL	2013
Faculty Panel: Great Debates & Updates in GI Malignancies,	New York, NY	2014
Strategies to Maximize Delivery of High Value Care for Patients with Advanced Cancer	University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL	2014
Strategies for Maximizing Value of Advanced Cancer Care	Virginia Commonwealth University, Massey Cancer Center, Richmond, VA	2014
Presentation to the Office of Hematology & Oncology Products (OHOP) and FDA members	Silver Spring, MD	2014
Informing Informed Consent: Defining and Validating Comprehension Panel	The Department of Health and Human Services Meeting of the Secretary's Advisory Committee on Human Research	2014

	Protections (SACHRP), Rockville, MD	
Strategies to Improve the Value of Oncology Care	University of North Carolina Lineberger Cancer Center, Cancer Outcomes Grand Rounds, Chapel Hill, NC	2014
21 st Century Cancer Care: Will New Models Lead to Better Care at Lower Cost?	The Alliance for Health Reform, Washington, DC	2014
Faculty Panel: Great Debates & Updates in GI Malignancies	New York, NY	2015
Setting Priorities: Career Planning at Different Stages for Women in Medical Oncology, panel	American Society of Clinical Oncology, Chicago, IL	2015
Optimizing Palliative Care for Patients: Patient-Centered Approaches to Communication, Decision Making, and Care Delivery PCORI Annual Meeting	Progress in Building a Patient-Centered Clinical Comparative Effectiveness Research Community, Crystal City, VA	2015
Survivorship, Outcomes and Risk SOAR Seminar	Memorial Sloan Kettering Cancer Center, New York, NY	2015
Capturing the Patient Perspective in Efficacy and Effectiveness Research: From Quality of Life to Toxicity to Digital-Health	Cancer Control Program Seminar, Ohio State University Comprehensive Cancer Center, Columbus, OH	2016
Discussant, Oral Abstract Session A	American Society of Clinical Oncology (ASCO), Quality Care Symposium, Chicago, IL	2016
Policy Issues in the Development and Use of Immunotherapies for Cancer	National Cancer Policy Forum Meeting, Washington DC	2016
Colorectal Cancer Plenary Session: Sidedness and Prognosis in Colorectal Cancer	American Society of Clinical Oncology (ASCO),	2016

	Annual Meeting, Chicago, IL	
Plenary Session: A Framework for Evaluating the Value of Progress in Cancer Therapy	American Society of Clinical Oncology (ASCO), Annual Meeting, Chicago, IL	2016
Education Session: What is Optimal Adjuvant Treatment for Stage II and III Rectal Cancer in 2016	American Society of Clinical Oncology (ASCO), Annual Meeting, Chicago, IL	2016
Plenary Session: ASCO Value Framework for Cancer Treatments	National Cancer Institute Annual Meeting, Rockville, MD	2016
Plenary Session, American Society of Clinical Oncology (ASCO) Value Framework for Cancer Treatments, Cancer Intervention and Surveillance Modeling Network (CISNET),	Annual Meeting, Rockville, MD	2016
Pilot to Populations: Quality, Efficacy and Effectiveness of Rectal Cancer Treatment	R2 Strength Program Visiting Professor Series, St. Louis, MO	2017
Improving Rectal Cancer Quality of Care	Tripartite ASCRS Annual Scientific Meeting, Seattle, WA American Society of Clinical Oncology (ASCO) Value Framework for Cancer Treatments, Cancer Intervention and Surveillance Modeling Network (CISNET), Annual Meeting, Rockville, MD	2017
Plenary Session: Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment	American Society of Clinical Oncology (ASCO), Annual Meeting, Chicago, IL	2017
Educational Session: Aligning Value and Precision Medicine	American Society of Clinical Oncology (ASCO), Annual Meeting, Chicago, IL	2017

Do All Patients with Locally Advanced Rectal Cancer Need Neoadjuvant Therapy? Improving Rectal Cancer Quality of Care Symposium	American Society of Colon and Rectal Surgeons (ASCRS), Seattle, WA	2017
DeLynn Endowed Lecture: Precision Public Health: High value strategies to decrease the burden of cancer on the health of communities	West Virginia University, Morgantown, WV	2017
AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)	Alliance for Clinical Trials in Oncology, Chicago, IL	2017
Advances in Colorectal Oncology: Chemotherapy instead of Radiation To Improve Local Tumor Control	Memorial Sloan Kettering Cancer Center, New York, NY	2017
Masonic Cancer Center Seminar: Bridging Efficacy and Effectiveness: Knowledge Translation through the Lens of Contemporary Management of Rectal Cancer	University of Minnesota, Minneapolis, MN	2018
Panel 3: Cancer, Health Justice, and Disparities Yale Conference: The Policy, Politics & Law of Cancer,	New Haven, CT	2018
Session 2: Emerging Scientific Focus Area	Research Center of Regional Excellence Investigators' Strategic Planning Meeting, Bethesda, MD	2018
Inaugural Cancer Health Care Delivery and Policy Symposium: PROs in Oncology from Efficacy to Effectiveness to Implementation	University of Pittsburgh School of Public Health and Medicine, Department of Health Policy and the Cancer Center, Pittsburgh, PA	2018
PROs to Improve Cancer Care Delivery: A translational journey from Feasibility to Efficacy, Effectiveness and Implementation	Vanderbilt-Ingram Cancer Center Nashville, TN	2018
The Real Challenges of "Real World" Data—Presentation to the NCI Healthcare Delivery Research Branch.	Bethesda, MD	2019
The PRISMM Phenomic Data System SEER Principal Investigators Meeting	Rockville, MD	2019

Real World Evidence to Inform Research and Clinical Decision making PMWC Precision Medicine World Conference	Santa Clara, CA	2019
Practical guide for launching a new study – reports from the field AACR Special Conference	San Diego, CA	2019
Multi-Stakeholder Panel – Post-Market Research and Development Considerations FDA-America Society of Clinical Oncology-Friends of Cancer Research Workshop on Development of Tissue	Silver Springs, MD	2019
Actionable social determinants of health and cancer care delivery-National Cancer Policy Forum workshop on health disparities	Washington DC	2019
Improving Health through Patient Reported Outcomes Annual Value in Cancer Care Summit, Fred Hutchinson	Seattle, WA	2019
Large Genomic Databases & Real-World Evidence	FDA-AACR Real World Evidence Workshop, Bethesda, MD	2019
Selection of Patient Reported Outcome Tools for Use in the Clinic, Self-Reported Measures of Function Patient Reported Outcomes in the Clinical Setting	MD Anderson Cancer Center, Houston, TX	2019
Genomic-phenomic data linkages to accelerate discovery in oncology: Obstacles and opportunities AACR, Advancing Precision Medicine Drug Development	San Diego, CA	2020
Making the Electronic Health Record work for Cancer Patients, Epic Corporation	Verona WI	2020
Patient Reported Outcomes in Oncology: From Research to Routine Visiting Professor, UCLA, The David Geffen School of Medicine and Research Themes and the Clinical and Translational Sciences Institute	Los Angeles, CA	2020
Minimizing Waste of Weight Based Medications and use of JW modifiers in Oncology-National Academy of Medicine Workshop	Virtual due to COVID-19	2020

Pragmatic Clinical Trial Designs in Cancer Care Delivery ASCO Quality Meeting (held remotely due to COVID-19)	Virtual due to COVID-19	2020
AACR Sustaining Member Virtual Roundtable Discussion: Precision Medicine and Real-World Evidence (held remotely due to COVID-19)	Virtual due to COVID-19	2020
NCI Future of Cancer Health Economics Research Conference (held remotely due to COVID-19)	Virtual due to COVID-19	2020
Co-Chair Call Meeting for Impact of ACA on Cancer Prevention and Care Workshop (held remotely due to COVID-19)	Virtual due to COVID-19	2020
Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer, The National Academies of Sciences, Engineering, and Medicine (held remotely due to COVID-19)	Virtual due to COVID-19	2021
Genomic-Phenomic linked data: Challenges and Opportunities. Population Sciences Research Seminar, Memorial Sloan Kettering Cancer Center, (held remotely due to COVID-19)	Virtual due to COVID-19	2021
The Impact of ACA on Cancer Prevention and Care: A Virtual Workshop, The National Academies of Science, Engineering, and Medicine (held remotely due to COVID- 19)	Virtual due to COVID-19	2021
Embracing Change, Advancing Person-Centered Care, The American Society for Radiation Oncology (ASTRO)	Presidential Symposium, Chicago, IL	2021
MD Anderson Outstanding Trainee and Leading Mentor Awards Event	MD Anderson, Houston, Texas (virtual due to pandemic)	2022
ASCO Clinical Science Symposium Is There a Ghost in the Machine? Putting Artificial Intelligence to Work	ASCO, Chicago, IL	2022
Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer: The PROSPECT Trial (Alliance N1048)	2023 ASCO Annual Meeting, Chicago, IL	2023
Opening Plenary Session at the AACR Annual Meeting 2023	Orlando, FL	2023
Early Cancer Detection with Blood Based Assays: Early Experience and the Path Forwards	Georgia Cancer Center Grand Rounds (Virtual)	2023

Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing	2023 ASCO Annual Meeting, Chicago, IL	2023
---	---------------------------------------	------

International

<i>Title</i>	<i>Institution/Location</i>	<i>Dates (yyyy)</i>
Estimating the Benefits and Risks of Prophylactic Surgical Strategies for Women with Hereditary Breast Cancer in the Face of Imperfect Information/Annual Meeting	German Cancer Society, Berlin, Germany	1998
Estimating the Benefit of Prophylactic Mastectomy for Women with and without Known Mutation in the BRCA Genes/Grand Rounds	Israel Medical Society, Jerusalem, Israel	1999
When and How Should We Measure Cost-Effectiveness in Oncology/Annual Meeting	European Society of Medical Oncology, Istanbul, Turkey	2006
Measuring the Quality of US Cancer Care/Seminar	International Union Against Cancer (UICC), Geneva, Switzerland	2008
The US Approach to Cancer System Quality Indicators/Seminar	Cancer Care Ontario, Toronto, Ontario, Canada	2009
Disparities in Outcomes of Colorectal Cancer Treatment/Meeting	CISNET, Rotterdam, Netherlands	2009
Prognostic and Predictive Markers for Patients with Colorectal Cancer and Lynch Syndrome	Workshop Tel Aviv, Jerusalem, Israel	2009
Comparative Effectiveness Research and International Research Collaborations in Cancer/Conference	American Association for Cancer Research (AACR), Dead Sea, Jordan	2010
Personalizing Treatment for Locally Advanced Rectal Cancer/Oncology Grand Rounds	Kantonsspital Aarau, Zurich, Switzerland	2010
Personalizing Treatment for Locally Advanced Rectal Cancer/Surgical Grand Rounds	Universitäts Hospital, Zurich, Switzerland	2010
When less is more: A view of CER from the USA	Australian Society of Medical Oncology, Adelaide, Australia	2011

Prognostic and Predictive Markers in Colon Cancer: When and How they are used for treatment decision making in the USA	Australian Society of Medical Oncology, Adelaide, Australia	2011
Identifying High Value Cancer Treatments: Patient, Physician and Public Health System Perspectives	Australian Society of Medical Oncology, Adelaide, Australia	2011
Evolving Treatment Strategies for Rectal Cancer	The Annual Meeting of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG), Toronto, Ontario, Canada	2012
Visiting Professor in residence (2 weeks) Evaluating Care Quality and Effectiveness in GI Oncology Argentinean Intergroup of Gastrointestinal Tumors Treatment (IATTGI)	Buenos Aries, Argentina	2013
Visiting Professor, Balancing Cure and Toxicity: Defining Optimal Multi-Modality Strategies for Management of Locally Advanced Rectal Cancer	SAKK Swiss Oncology Society Meeting, St. Gallen, Switzerland	2014
Invited speaker: Population-wide colorectal cancer control	Autonomous University of Madrid, Spain	2016
Invited speaker Quantifying the Impact of Precision Medicine at the Population Level	European Society for Medical Oncology (ESMO) Copenhagen, Denmark	2016
Invited speaker, Value Frameworks in Oncology ARCC Conference,	Cancer Care Ontario Plenary Session, Toronto, Ontario Canada	2017
Improving outcomes for patients with colorectal cancer: the trials we do and the trials we don't do.	Visiting Professor, Cancer Research Institute of the University of Vienna, Vienna, Austria.	2017
Invited speaker, How relevant are the ESMO and ASCO clinical benefit scales: Do they impact our practice?	ESMO 19th World Congress GI Meeting, Barcelona, Spain	2017
Visiting Professor Lectio Magistralis, Patient-reported symptom monitoring during cancer treatment	Milan, Italy	2018

Visiting Professor, Integrating Genomics and Phenomics to Realize the Value of Precision Medicine	The University of Milan, Milan, Italy	2018
Visiting Professor, Pan-Asian Oncology Meeting, Integrating Patient Reported Outcomes into Oncology	Hong Kong, China	2018
Visiting Professor, NHS The PRISMM Model: a phenomic data standard for curation of reliable “Real world” cancer outcomes including recurrence and progression	European – US Workshop on Cancer Data, London, United Kingdom	2019
Invited speaker, Precision medicine in cancer: Integrating Genomics and Phenomics	Chinese Academy of Medical Science Summit, Chengdu, China	2019
Invited speaker, Validity of Real-World Evidence ESMO 21 st World Congress on Gastrointestinal Cancer, Barcelona, Spain Invited speaker, Integrating Patient Reported Outcomes in Oncology, European Society for Medical Oncology (ESMO) Barcelona Spain Invited speaker, Real World Evidence and Phenomic Data Standards for Regulatory Decision Making	European Society for Medical Oncology (ESMO) Barcelona, Spain	2019 2019 2019
Invited speaker, discussant, panelist, Value Frameworks in Oncology-First International Summit on Interventional Pharmacoeconomics Tel Aviv, Israel	Virtual due to COVID-19	2020
Visiting Professor, Princess Margaret Cancer Center, Harmonizing genomic and phenomic data Toronto, Canada	Virtual due to COVID-19	2020

S. BIBLIOGRAPHY

Peer-reviewed Research Articles:

1. Greenstein AJ, Sachar DB, Gibas A, **Schrag D**, Heimann T, Janowitz HD, Aufses AH Jr. Outcome of toxic dilatation in ulcerative and Crohn’s colitis. *J Clin Gastroenterol*. 1985 Apr;7(2):137-43. PMID: 4008909.
2. **Schrag D**, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. *N Engl J Med*. 1997;336(20):1465-71. PMID: 9148160.
3. Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, **Schrag D**, Gallinger S, Kaback M, King MD, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APCI1307K allele and breast cancer risk. *Nat Genet*. 1998;20(1):13-4. PMID: 9731522.

4. Syngal S, Weeks JC, **Schrag D**, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. *Ann Intern Med*. 1998;129(10):787-96. PMID: 9841584.
5. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, **Schrag D**, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. *J Clin Oncol*. 2000;18(14):2728-32. PMID: 10894872.
6. **Schrag D**, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. Influence of hospital procedure volume on outcomes following surgery for colon cancer. *JAMA*. 2000;284(23):3028-35. PMID: 11122590.
7. **Schrag D**, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. *JAMA*. 2000; 283(5):617-24. PMID: 10665701.
8. Syngal S, **Schrag D**, Falchuk M, Tung N, Farraye FA, Chung D, Wright M, Whetsell A, Miller G, Garber JE. Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. *JAMA*. 2000;284(7):857-60. PMID: 10938175.
9. Bach PB, Cramer LD, **Schrag D**, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. *N Engl J Med*. 2001;345(3):181-8. PMID: 11463014.
10. Bach PB, **Schrag D**, Nierman DM, Horak D, White P Jr, Young JW, Groeger JS. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. *Blood*. 2001;98(12):3234-40. PMID: 11719359.
11. **Schrag D**, Cramer LD, Bach PB and Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. *J Natl Cancer Inst*. 2001;93(11):850-7. PMID: 11390534.
12. **Schrag D**, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results-Medicare. *J Clin Oncol*. 2001;19(17):3712-8. PMID: 11533092.
13. Bach PB, **Schrag D**, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. *JAMA*. 2002;287(16):2106-13. PMID: 11966385.
14. Begg CB, Riedel ER, Bach PB, Kattan MW, **Schrag D**, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. *N Engl J Med*. 2002;346(15):1138-44. PMID: 11948274.
15. **Schrag D**, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. *Ann Surg*. 2002;236(5):583-92. PMID: 12409664. PMCID: PMC1422616.
16. **Schrag D**, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. *J Clin Oncol*. 2002;20(19):3999-4005. PMID: 12351597.

17. Warren JL, Klabunde CN, **Schrag D**, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care*. 2002;40(8 Suppl):IV-3- 18. PMID: 12187163.
18. Bach PB, Guadagnoli E, **Schrag D**, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. *Med Care*. 2002;40 IV, 19-25. PMID: 12187164.
19. Panageas KS, **Schrag D**, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. *Ann Intern Med*. 2003;139(8):658-65. PMID: 14568854.
20. **Schrag D**, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. *J Natl Cancer Inst*. 2003;95(8):588-97. PMID: 12697851.
21. **Schrag D**, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. *J Surg Oncol*. 2003;83(2):68-78. PMID: 12772198.
22. Meyerhardt JA, Catalano PJ, **Schrag D**, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. *Ann Intern Med*. 2003;139(8):649-57. PMID: 14568853.
23. Bach PB, Pham HH, **Schrag D**, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. *N Engl J Med*. 2004;351(6):575-84. PMID: 15295050.
24. Basch EM, Thaler HT, Shi W, Yakren S, **Schrag D**. Use of information resources by patients with cancer and their companions. *Cancer*. 2004;100(11):2476-83. PMID: 15160355.
25. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, **Schrag D**, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RK, Willett CG, MacDonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. *J Clin Oncol*. 2004;22(1):166-74. PMID: 14701779.
26. Rizk NP, Bach PB, **Schrag D**, Bains MS, Turnbull MD, Karpeh M, Brennan MF, Rusch VW. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. *J Am Coll Surg*. 2004; 198(1):42-50. PMID: 14698310.
27. Temple LK, Hsieh L, Wong WD, Saltz L, **Schrag D**. Use of surgery among elderly patients with stage IV colorectal cancer. *J Clin Oncol*. 2004 Sep 1;22(17):3475-84. PMID: 15337795.
28. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz G, Tse A, Hamilton A, Pan D, **Schrag D**, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *J Clin Oncol*. 2005;20:1803-10. PMID: 15677699.

29. **Schrag D**, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, Begg CB. Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the Medicare population. *Urology*. 2005;65:1118-25. PMID: 15922428.
30. Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, **Schrag D**. Patient online self-reporting of toxicity symptoms during chemotherapy. *J Clin Oncol*. 2005;23:3552-3561. PMID: 15908666.
31. Temple LK, Bacik J, Savatta SG, Gottesman L, Paty PB, Weiser MR, Guillem JG, Minsky BD, Kalman M, Thaler HT, **Schrag D**, Wong WD. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. *Dis Colon Rectum*. 2005;48:1353-65. PMID: 15868235.
32. Pham HH, **Schrag D**, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. *JAMA*. 2005 Jul 27;294(4):473-81. PMID: 16046654.
33. **Schrag D**, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. *J Natl Cancer Inst*. 2005 Aug 17;97(16):1221-4. PMID: 16106027.
34. Elkin EB, Hudis C, Begg CB, **Schrag D**. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. *Cancer*. 2005. Sep 15;104(6):1149-57. PMID: 16088887.
35. Hillner BE, **Schrag D**, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. *Cancer*. 2005 Sep 21;104(9):1871-84. PMID: 16177989.
36. Chiao EY, Krown SE, Stier EA, **Schrag D**. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. *J Acquir Immune Defic Syndr*. 2005 Dec 1;40(4):451-455. PMID: 16280701.
37. **Schrag D**, Earle CC, Xu F, Panageas KS, Yabroff KO, Bristow RW, Trimble EL, Warren JL. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. *J Natl Cancer Inst*. 2006 Feb 1;98(3):163-71. PMID: 16449676.
38. Earle CC, **Schrag D**, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. *J Natl Cancer Inst*. 2006 Feb 1;98(3):172-80. PMID: 16449677.
39. Bickell NA, Wang JJ, Oluwole S, **Schrag D**, Godfrey H, Hiotis K, Mendez J, Guth AA. Missed opportunities: racial disparities in adjuvant breast cancer treatment. *J Clin Oncol*. 2006 Mar 20;24(9):1357-62. PMID: 16549830.
40. Indurkha A, Mitra N, **Schrag D**. Using propensity scores to estimate the cost effectiveness of medical therapies. *Stat Med*. 2006 May 15;25(9):1561-76. PMID: 16158412.

41. **Schrag D**, Xu F, Hanger M, Elkin E, Bickell NA, Bach PB. Fragmentation of Care for Frequently Hospitalized Urban Residents. *Med Care*. 2006 Jun;44(6):560-7. PMID: 16708005.
42. Elkin EB, Hurria A, Mitra N, **Schrag D**, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observation cohort. *J Clin Oncol*. 2006 Jun 20;24(18):2757-64. PMID: 16782916.
43. Vogelaar I, van Ballegooijen M, **Schrag D**, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.?: mortality projections for scenarios of risk-factor modification, screening and treatment. *Cancer*. 2006 Oct 1;107(7):1624-33. PMID: 16933324.
44. Bekelman JE, Rosenzweig KE, Bach PB, **Schrag D**. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2006 Oct 1;66(2):492-9. PMID: 16814952.
45. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, **Schrag D**. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. *Lancet Oncol*. 2006 Nov;7(11):903-9. PMID: 17081915.
46. Ballas LK, Elkin EB, **Schrag D**, Minsky BD, Bach PB. Radiation therapy facilities in the United States. *Int J of Radiat Oncol Biol Phys*. 2006 Nov;6(4):1204-11. PMID: 17145535.
47. **Schrag D**, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. *J Clin Oncol*. 2007 Jan;25(2):233-7. PMID: 17210946.
48. Pham HH, **Schrag D**, O'Malley A, Wu B, Bach PB. Care Patterns in Medicare and their Implications for Pay for Performance. *N Engl J Med*. 2007 Mar 15;356(11):1130-39. PMID: 17360991.
49. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, **Schrag D**. When you look matters: the effect of assessment schedule on progression-free survival. *J Natl Cancer Inst*. 2007 Mar 21;99(6):428-32. PMID: 17374832.
50. Panageas KS, **Schrag D**, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. *Stat Med*. 2007 Apr 30;26(9):2017-35. PMID: 17016864.
51. Neuman HB, **Schrag D**, Cabral C, Weiser MR, Paty PB, Guillem JG, Minsky BD, Wong WD, Temple LK. Can differences in bowel function after surgery for rectal cancer be identified by the European organization for research and treatment of cancer quality of life instrument? *Ann Surg Oncol*. 2007 May;14(5):1727-34. PMID: 17265117.
52. Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, **Schrag D**. Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities. *J Am Med Inform Assoc*. 2007 May-Jun;14(3):264-68. PMID: 17329732.

53. O'Malley A, Pham HH, Wu B, **Schrag D**, Bach PB. Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics. *Med Care*. 2007 Jun;45:562-70. PMID: 17515784.
54. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, **Schrag D**, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. *J Natl Cancer Inst*. 2007 Aug 1;99(15):1171-7. PMID: 17652279.
55. Klabunde CN, Legler JM, Warren JL, Baldwin LM, **Schrag D**. A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients. *Am J of Epid*. 2007 Aug 18;17(8):584-90. PMID: 17531502.
56. Quah HM, Joseph R, **Schrag D**, Shia J, Guillem JG, Paty P, Temple LK, Wong WD, Weiser MR. Young age influences treatment but not outcome of colon cancer. *Ann Surg Oncol*. 2007 Oct;14(10):2759-2765. PMID: 17593332.
57. Elkin EB, Kim SH, Casper ES, Kissane DW, **Schrag D**. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. *J Clin Oncol*. 2007 Nov 20;25(33):5275-80. PMID: 18024875.
58. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, **Schrag D**. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. *J Clin Oncol*. 2007 Dec 1;25(34):5374-80. PMID: 18048818.
59. Bekelman JE, Jang T, Liu Y, Basch E, Zelefsky M, **Schrag D**. Variation in Adherence to External Beam Radiotherapy Quality Measures Among Elderly Men with Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2007 Dec 1;69:1456-66. PMID: 17689880.
60. Elkin EB, Ishill N, Riley GF, Bach BP, Gonen M, Begg CB, **Schrag D**. Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. *J Natl Cancer Inst*. 2008;100(14):1013-21. PMID: 18612131.
61. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, **Schrag D**, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. *J Clin Oncol*. 2008 Jan 20;26(3):380-5. PMID: 18202413.
62. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, **Schrag D**, Temple LK. Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. *Dis Colon Rectum*. 2008 Feb;51(2):147-53. PMID: 18180997.
63. Vickers AJ, Bianco FJ, Gonen M, Cronin AM, Eastham JA, **Schrag D**, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. *Eur Urol*. 2008 May;53(5):960-966. PMID: 18207316.

64. Quah HM, Chour JF, Gonen M, Shia J, **Schrag D**, Landmann R, Guillem JG, Paty PB, Temple L, Wong WD, Weiser MR. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. *Dis Colon Rectum*. 2008 May;51(5):503-507. PMID: 18322753.
65. Quah HM, Chou JF, Gonen M, Shia J, **Schrag D**, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. *Cancer*. 2008 Jul 1;113(1):57-64. PMID: 18442099.
66. Pham HH, O'Malley AS, Bach PB, Saiontz-Martinez C, **Schrag D**. Primary Care Link to Other Physicians Through Medicare Patients: The Scope of Care Coordination. *Ann Int Med*. 2009 Feb 17;150(4):1-7. PMID: 19221375.
67. Pham HH, Landon BE, Reschovsky JD, Wu B, **Schrag D**. Rapidity and Modality of Imaging for Acute Low Back Pain in Elderly Patients. *Arch Intern Med*. 2009 May 25;169(10). PMID: 19468091.
68. Yabroff R, Warren JL, Banthin J, **Schrag D**, Mariotto A, Lawrence W, Meekins A, Topor M, Brown M. Comparison of Approaches for Estimating Prevalence Costs of Care for Cancer Patients. What is the Impact of Data Source? *Med Care*. 2009;47(7) Supp 1:64-9. PMID: 19536016.
69. Yabroff R, Warren JL, **Schrag D**, Mariotto A, Lawrence W, Meekins A, Topor M, Brown M. Comparison Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients. *Med Care*. 2009;47(7) Supp 1:56-63. PMID: 19536010.
70. **Schrag D**, Virnig BA, Warren JL. Linking Tumor Registry and Medicaid Claims to Evaluate Cancer Care Delivery. *Health Care Financ Rev*. 2009;30(4):61-73. PMID: 19719033.
71. Phelps AC, Maciejewski PK, Nilsson M, Balboni TA, Wright AA, Paulk ME, Trice E, **Schrag D**, Peteet JR, Block SD, Prigerson HG. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. *JAMA*. 2009;301(11):1140-7. PMID: 19293414.
72. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, **Schrag D**. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. *J Natl Cancer Inst*. 2009 Dec 2;101(23):1624-32. PMID: 19920223.
73. Ku GY, O'Reilly EM, Saltz LB, **Schrag D**, Maki RG, Kelson DP, Ilson DH. Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. *Cancer Invest*. 2009;27(4):402-6. PMID: 19219674.
74. Tew WP, Radovich D, O'Reilly E, Schwartz G, **Schrag D**, Saltz LB, Kelson DP, Kepler S, Ilson DH. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. *Invest New Drugs*. 2009;27(4):366-73. PMID: 18956138.
75. Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, **Schrag D**. Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers. *Ann Surg*. 2009 Aug;250(2):260-7. PMID: 19638922.

76. Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, **Schrag D**. Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. *J Surg Oncol*. 2009 Aug 20;100:525-28. PMID: 19697351.
77. Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong Y, Benson AB, Shibata S, **Schrag D**. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: An NCCN Institutional Analysis. *J Natl Compr Canc Netw*. 2009 Sep;7(8):895-904. PMID: 19755049.
78. Gönen M, **Schrag D**, Weiser MR. Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer. *J Clin Oncol*. 2009;27(36):6166-71. PMID: 19901106.
79. Sima CS, Panageas KS, Heller G, **Schrag D**. Analytical Strategies for Characterizing Chemotherapy Diffusion with Patient-Level Population-Based Data. *Appl Health Econ Health Policy*. 2010;8(1):37-51. PMID: 20038192.
80. Jang JL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, **Schrag D**. Physician visits prior to treatment for clinically localized prostate cancer. *Arch Intern Med*. 2010 Mar 8;170(5):440-50. PMID: 20212180.
81. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, **Schrag D**, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH. Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer. *JAMA*. 2010 Mar;303(11):1037-45. PMID: 20233821.
82. Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, **Schrag D**. Geographic Access and the Use of Screening Mammography. *Med Care*. 2010 Apr;48(4):349-56. PMID: 20195174.
83. Chou JF, Row D, Gonen M, Liu YH, **Schrag D**, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. *Cancer*. 2010 Jun 1;116(11):2560-70. PMID: 20499400.
84. Rajput A, Romanus D, Weiser MR, ter Veer A, Niland J, Wilson J, Skibber JM, Wong YN, Benson A, Earle CC, **Schrag D**. Meeting the 12 lymph node (LN) benchmark in colon cancer. *J Surg Oncol*. 2010 Jul;102(1):3-9. PMID: 20578172.
85. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, **Schrag D**, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol*. 2010 Aug 1;28(22):3617-22. PMID: 20606091.
86. Sima CS, Panageas KS, **Schrag D**. Cancer screening among patients with advanced cancer. *JAMA*. 2010 Oct 13;304(14):1584-91. PMID: 20940384.

87. Yung RL, Chen K, Abel GA, Gesten GA, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, **Schrag D**. Cancer Disparities in the Context of Medicaid Insurance: A Comparison of Survival for Acute Myeloid Leukemia and Hodgkin's Lymphoma by Medicaid Enrollment. *The Oncologist*. 2011; 16:1082-1091. PMID: 21873583.
88. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, **Schrag D**, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1-2 study of everolimus in advanced hepatocellular carcinoma. *Cancer*. 2011 Apr 27;117(22):5094-102. PMID: 21538343.
89. Martin MY, Pisu M, Oster RA, Urmie JM, **Schrag D**, Huskamp HA, Lee J, Kiefe CI, Fouad MN. Racial variation in willingness to trade financial resources for life-prolonging cancer treatment. *Cancer*. 2011 Apr 26;117(15):3476-84. PMID: 21523759.
90. Sher DJ, Neville BA, Chen AB, **Schrag D**. Predictors of IMRT and Conformal Radiotherapy Use in Head and Neck Squamous Cell Carcinoma: A SEER-Medicare Analysis. *Int J Radiat Oncol Biol Phys*. 2011 May 17;81(4):197-206. PMID: 21596483.
91. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, **Schrag D**, Bhargava P, Meyerhardt JA, Wlopin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. *Ann Oncol*. 2011 Jun;22(6):1367-73. PMID: 21217058.
92. Boscoe FP, **Schrag D**, Chen K, Roohan PJ, Schymura MJ. Building Capacity to Assess Cancer Care in the Medicaid Population in New York State. *Health Serv Res*. 2011 Jun;46(3):805-20. PMID: 21158856.
93. Greenberg CC, Lipsitz SR, Neville B, In H, Hevelone N, Porter SA, Weeks C, Jha AK, Gawande AA, **Schrag D**, Weeks JC. Receipt of Appropriate Surgical Care for Medicare Beneficiaries With Cancer. *Arch Surg*. 2011 Jun 20;146(10):1128-34. PMID: 21690439.
94. Chen AB, Neville BA, Sher DJ, Chen K, **Schrag D**. Survival Outcomes After Radiation Therapy for Stage III Non-Small-Cell Lung Cancer After Adoption of Computed Tomography-Based Simulation. *J Clin Oncol*. 2011 Jun 10;29(17):2305-11. PMID: 21537034.
95. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, **Schrag D**, Fuchs CS. Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer. *J Clin Oncol*. 2011 Aug 20;29(24):3255-62. PMID: 21768462.
96. Zafar SY, Malin JL, Grambow SC, Abbott DH, **Schrag D**, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. *Cancer*. 2011 Aug 16; 11 (1) :354. PMID: 21846341.
97. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gönen M, **Schrag D**, Basch E. Reliability of adverse symptom event reporting by clinicians. *Qual Life Res*. 2012 Sep;21(7):1159-64.. PMID: 21984468.

98. Weiser MR, Gönen M, Chou JF, Kattan MW, **Schrag D**. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. *J Clin Oncol*. 2011 Dec 20;29(36):4796-802. PMID: 22084366.
99. Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, **Schrag D**. Outpatient use of low molecular weight heparin monotherapy for first-line treatment venous thromboembolism in advanced cancer. *Oncologist*. 2012;17(3):419-27. PMID: 22334451.
100. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, **Schrag D**. Carboplatin and Paclitaxel Withvs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer. *JAMA*. 2012;307(15):1593-1601. PMID: 22511687.
101. Panageas KS, Sima CS, Liberman L, **Schrag D**. Use of high technology imaging for surveillance of early stage breast cancer. *Breast Cancer Res Treat*. 2012 Jan;131(2):663-70. PMID: 21947679.
102. Elkin EB, Snow JG, Leoce NM, Atoria CL, **Schrag D**. Mammography capacity and appointment wait times: barriers to breast cancer screening. *Cancer Causes Control*. 2012 Jan;23(1):45-50. PMID: 22037904.
103. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, **Schrag D**. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. *J Natl Cancer Inst*. 2012 Feb 8;104(3):211-27. PMID: 22266473.
104. Meyerhardt JA, Li L, Sanoff HK, Carpenter W 4th, **Schrag D**. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. *J Clin Oncol*. 2012 Feb 20;30(6):608-15. PMID: 22253466.
105. Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, **Schrag D**. Cancer and Leukemia Group B. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). *J Pain Symptom Manage*. 2012 Feb;43(2):205-17. PMID: 22104618.
106. Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gonen M, Kuk D, Weiser M, Saltz L, **Schrag D**, Goodman K, Paty P, Guillem J, Nash GM, Temple L, Shia J, Schwartz LH. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. *Eur Radiol*. 2012 Apr;22(4):821-31. PMID: 22101743.
107. Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, **Schrag D**. Initiation of Adjuvant Hormone Therapy by Medicaid Insured Women with Non-metastatic Breast Cancer; *J Natl Cancer Inst*. 2012 Jun;104(14):1102-5. PMID: 22773822.
108. Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, **Schrag D**. Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. *J Clin Oncol*. 2012 Jul 20;30(21):2624-34. PMID: 22665536.

109. Morikawa T, Tanaka N, Kuchiba A, Noshu K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, **Schrag D**, Fuchs CS, Ogino S. Predictors of Lymph Node Count in Colorectal Cancer Resections: Data From US Nationwide Prospective Cohort Studies. *Arch Surg*. 2012 Aug;147(8):715-23. PMID: 22508672.
110. Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, **Schrag D**. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A Population-based analysis. *Cancer*. 2012 Sep 1;118(17):4309-20. PMID: 22294436.
111. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, **Schrag D**. Patients' Expectations about Chemotherapy for Advanced Cancer. *N Engl J Med*. 2012 Oct;367:1616-25. PMID: 23094723
112. Knudsen AB, Hur C, Gazelle GS, **Schrag D**, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. *Ann Intern Med*. 2012 Nov 6;157(9):611-20. PMID: 23128861.
113. Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, **Schrag D**, Hankey BF. The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. *Cancer*. 2012 Nov 15;118(22):5652-62. PMID: 22569947.
114. Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, Tai E, **Schrag D**. Measuring colorectal cancer care quality for the publicly insured in New York State. *Cancer Med*. 2012 Dec;1(3):363-71. PMID: 23342286.
115. Abel GA, Chen K, Taback N, Hassett MJ, **Schrag D**, Weeks JC. Impact of oncology-related direct-to-consumer advertising: Association with appropriate and inappropriate prescriptions. *Cancer*. 2013 Mar 1;119(5):1065-72. PMID: 23132702.
116. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, **Schrag D**, Warren JL, Hornbrook MC, Weeks JC. Validating Billing?Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts. *Med Care*. 2014 Oct;52(10):e65-73. PMID: 23222531.
117. Dodgion CM, Neville BA, Lipsitz SR, Hu YY, **Schrag D**, Breen E, Greenberg CC. Do older Americans undergo stoma reversal following low anterior resection for rectal cancer? *J Surg Res*. 2013 Jul;183(1):238-45. PMID: 23298948.
118. Khrizman P, Niland JC, Ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, Shibata S, Skibber JM, Weiser MR, **Schrag D**, Benson AB 3rd. Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis. *J Clin Oncol*. 2013 Jan 1; 31(1):30-8. PMID: 23169502.
119. McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, **Schrag D**, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric

- assessment in older patients with gastrointestinal malignancy. *Oncologist*. 2013 Jan 3;18(1):64-72. PMID: 23287880.
120. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, **Schrag D**. Palliative Radiation Therapy Practice in Patients With Metastatic Non-Small-Cell Lung Cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. *J Clin Oncol*. 2013 Feb 10;31(5):558-64. PMID: 23295799.
121. Zafar SY, Peppercorn JM, **Schrag D**, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP. The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience. *Oncologist*. 2013 Feb 26; 18(4):381-90. PMID: 23442307.
122. Greenberg CC, Wind JK, Chang GJ, Chen RC, **Schrag D**. Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEClIDE Cancer Consortium. *J Comp Eff Res*. 2013 Mar;2(2):117-25. PMID: 24236554.
123. Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, **Schrag D**, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. *Oncologist*. 2013 April 11;18(4):377-8. PMID: 23580238
124. Elkin EB, Paige NJ, Pinheiro LC, Atoria CL, **Schrag D**. Changes in access to screening mammography, 2008-2011. *Cancer Causes Control*. 2013 May;24(5):1057-9. PMID: 23468282.
125. Johnson BE, Weeks JC, **Schrag D**. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. *Cancer*. 2013 Jun 1;119(11):2048-60. PMID: 23564469.
126. Brooks GA, Li L, Sharma DB, Weeks JC, Hassett MJ, Yabroff KR, **Schrag D**. Regional Variation in Spending and Survival for Older Adults With Advanced Cancer. *J Natl Cancer Inst*. 2013 May 1;105(9):634-42. PMID: 23482657.
127. Yeh, JM, Hur, C, **Schrag D**, Kuntz, KM, Ezzati, M, Stout, N, Ward, Z, Goldie, SJ. Contribution of H. pylori and Smoking Trends to US Incidence of Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation Model. *PLoS Med*. 2013 May 21;10(5):1-13. PMID: 23700390.
128. Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, **Schrag D**, Punglia RS. Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma In Situ. *J Natl Cancer Inst*. 2013 Jun 5;105(11):774-781. PMID: 23644480.
129. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, **Schrag D**. Expectations About the Effectiveness of Radiation Therapy Among Patients With Incurable Lung Cancer. *J Clin Oncol*. 2013 Jul 20;31(21):2730-5. PMID: 23775958.

130. Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Weeks JC, Schymura MJ, **Schrag D**. Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California. *J Clin Oncol*. 2013 Jul 10;31(20):2569-79. PMID: 23733768.
131. Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, **Schrag D**, Basch E. Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. *J Clin Oncol*. 2013 Jul 10;31(20):2580-5. PMID: 23733753.
132. Chawla N, Yabroff KR, Mariotto A, McNeel T, **Schrag D**, Warren J. PS1-39: Diagnosis Codes for Cancer Metastasis on Medicare Claims Have Limited Accuracy and Completeness. *Clin Med Res*. 2013 Sep;11(3):131. PMCID: PMC3788546.
133. Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, **Schrag D**, Temel JS, Schnipper L. Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum. *J Clin Oncol*. 2013 Nov 10;31(32):4151-7. PMID: 24127450.
134. Zullig LL, Peppercorn JM, **Schrag D**, Taylor DH Jr, Lu Y, Samsa G, Abernethy AP, Zafar SY. Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. *J Oncol Pract*. 2013 Nov;9(6S):60s-63s. PMID: 29431038.
135. Elkin EB, Atoria CL, Leoce N, Bach PB, **Schrag D**. Changes in the availability of screening mammography, 2000-2010. *Cancer*. 2013 Nov 1;119(21):3847-53. PMID: 23943323.
136. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, **Schrag D**, Wong SL, Benson AB 3rd; American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol*. 2013 Dec 10;31(35):4465-70. PMID: 24220554.
137. Neuman HB, Weiss JM, **Schrag D**, Ronk K, Havlena J, Loconte NK, Smith MA, Greenberg CC. Patient Demographic and Tumor Characteristics Influencing Oncologist Follow-Up Frequency in Older Breast Cancer Survivors. *Ann Surg Oncol*. 2013 Dec;20(13):4128-36. PMID: 23943027.
138. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, **Schrag D**. Secular Trends in Colon and Rectal Cancer Relative Survival. *J Natl Cancer Inst*. 2013 Dec 4;105(23):1806-13. PMID: 24174654.
139. Martin MY, Fouad MN, Oster RA, **Schrag D**, Urmie J, Sanders S, Pisu M. What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups. *Support Care Cancer*. 2014 Jan;22(1):233-44. PMID: 24037412.
140. Reyngold M, Niland J, Ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, **Schrag D**, Skibber JM, Small W Jr, Weiser M, Wilkinson N, Goodman KA. Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. *J Natl Compr Canc Netw*. 2014 Feb;12(2):235-43. PMID: 24586085.
141. Abrams TA, Meyer G, **Schrag D**, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. *J Natl Cancer Inst*. 2014 Feb;106(2). PMID: 24511107.

142. Brooks GA, Abrams TA, Meyerhardt JA, Enzinger PC, Sommer K, Dalby CK, Uno H, Jacobson JO, Fuchs CS, **Schrag D**. Identification of potentially avoidable hospitalizations in patients with GI cancer. *J Clin Oncol*. 2014 Feb 20;32(6):496-503. PMID: 24419123.
143. **Schrag D**, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol*. 2014 Feb 20;32(6). PMID: 24419115.
144. Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, **Schrag D**, Basch E; NCI PRO-CTCAE Study Group. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Qual Life Res*. 2014 Feb;23(1):257-69. PMID: 23868457.
145. Wang Y, **Schrag D**, Brooks GA, Dominici F. National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010. *Cancer*. 2014 Apr 1;120(7):1050-8. PMID: 24382787.
146. Arvold ND, Wang Y, Zigler C, **Schrag D**, Dominici F. Hospitalization burden and survival among older glioblastoma patients. *Neuro-Oncology*. 2014 Apr 28;1-11. PMID: 24778086.
147. Bestvina CM, Zullig LL, Rushing C, Chino F, Samsa GP, Altomare I, Tulsy J, Ubel P, **Schrag D**, Nicolla J, Abernethy AP, Peppercorn J, Zafar SY. Patient-oncologist cost communication, financial distress, and medication adherence. *J Oncol Pract*. 2014 May;10(3):162-7. PMID: 24839274.
148. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, **Schrag D**, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. *Oncologist*. 2014 Jun;19(6):637-8. PMID: 24821822.
149. Weeks JC, Uno H, Taback N, Ting G, Cronin A, D'Amico TA, Friedberg JW, **Schrag D**. Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of Cancer: A Multi-institutional Cohort Study. *Ann Intern Med*. 2014 Jul 1;161(1):20-30. PMID: 24979447.
150. Tejani MA, Ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, **Schrag D**, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ. Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. *J Natl Compr Canc Netw*. 2014 Aug;12(8):1123-30. PMID: 25099444.
151. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, **Schrag D**, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*. 2014 Aug 1;32(22):2380-5. PMID: 24982461.

152. Wong AC, Stock S, **Schrag D**, Kahn KL, Salz T, Charlton ME, Rogers SO Jr, Goodman KA, Keating NL. Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer. *J Oncol Pract*. 2014 Sep;10(5):e360-7. PMID: 24986112.
153. Trinh QD, **Schrag D**. Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population: Adequate Data Are Neither the Same as Nor the Enemy of Perfect Data. *JAMA Intern Med*. 2014 Sep;174(9):1468-9. PMID: 25023522.
154. Chawla N, Yabroff KR, Mariotto A, McNeel TS, **Schrag D**, Warren JL. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. *Ann Epidemiol*. 2014 Sep;24(9):666-72, 672. PMID: 25066409.
155. Dodgion CM, Neville BA, Lipsitz SR, **Schrag D**, Breen E, Zinner MJ, Greenberg CC. Hospital variation in sphincter preservation for elderly rectal cancer patients. *J Surg Res*. 2014 Sep;191(1):161-8. PMID: 24750983.
156. Kehl KL, Arora NK, **Schrag D**, Ayanian JZ, Clauser SB, Klabunde CN, Kahn KL, Fletcher RH, Keating NL. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. *J Natl Cancer Inst*. 2014 Sep 13;106(10). PMID: 25217775.
157. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, **Schrag D**. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst*. 2014 Sep 29;106(9). PMID: 25265940.
158. Brooks GA, Li L, Uno H, Hassett MJ, Landon BE, **Schrag D**. Acute hospital care is the chief driver of regional spending variation in medicare patients with advanced cancer. *Health Aff (Millwood)*. 2014 Oct 1;33(10):1793-800. PMID: 25288424.
159. Greenberg CC, Habel LA, Hughes ME, Nekhlyudov L, Achacoso N, Acton L, **Schrag D**, Jiang W, Edge S, Weeks JC, Punglia RS. Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ. *Ann Surg Oncol*. 2014 Nov;21(12):3766-73. PMID: 24859938.
160. Yeo H, Niland J, Milne D, Veer AT, Bekaii-Saab T, Farma JM, Lai L, Skibber JM, Small W Jr, Wilkinson N, **Schrag D**, Weiser MR. Incidence of minimally invasive colorectal cancer surgery at national comprehensive cancer network centers. *J Natl Cancer Inst*. 2014 Dec 19;107(1). PMID: 25527640.
161. Lee KH, Haneuse S, **Schrag D**, Dominici F. Bayesian semi-parametric analysis of semi-competing risks data: investigating hospital readmission after a pancreatic cancer diagnosis. *J R Stat Soc Ser C Appl Stat*. 2015 Feb 1;64(2):253-273. PMID: 25977592.
162. Hiatt RA, Tai CG, Blayney DW, Deapen D, Hogarth M, Kizer KW, Lipscomb J, Malin J, Phillips SK, Santa J, **Schrag D**. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. *J Natl Cancer Inst*. 2015 Mar 11;107(5). PMID: 25766400.

163. Brooks, GA, Jacobson JO, **Schrag, D**. Clinician perspectives on potentially avoidable hospitalizations in patients with cancer. *JAMA Oncol*. 2015 April;1(1):109-110. PMID: 26146663.
164. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, **Schrag D**, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. *J Clin Oncol*. 2015 Aug 10;33(23):2563-77. PMID: 26101248.
165. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, **Schrag D**, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JAMA Oncol*. 2015 Nov;1(8):1051-9. PMID: 26270597.
166. Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, **Schrag D**, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF; Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach. *Eur Urol*. 2015 Nov;68(5):891-8. PMID: 26129856.
167. Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Schymura MJ, **Schrag D**. High intensity end-of-life care among adolescent and young adult cancer patients in the New York State Medicaid Program. *Med Care*. 2015 Dec;53(12):1018-26. PMID: 26492211.
168. Enzinger AC, Zhang B, **Schrag D**, Prigerson HG. Outcomes of prognostic disclosure: Associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. *J Clin Oncol*. 2015 Nov 10;33(32):3809-16. PMID: 26438121.
169. Garcia-Aguilar J, Glynne-Jones R, **Schrag D**. Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. *Am Soc Clin Oncol Educ Book*. 2016;35:92-102. PMID: 27249690.
170. Brooks GA, Cronin AM, Uno H, **Schrag D**, Keating NL, Mack JW. Intensity of Medical Interventions between diagnosis and death in patients with advanced lung and colorectal cancer: A CanCORS analysis. *J Palliat Med*. 2016 Jan;19(1):42-50. PMID: 26600474.
171. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, **Schrag D**. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. *J Clin Oncol*. 2016 Feb 20;34(6):557-65. PMID: 26644527.

172. Hassett MJ, Jiang W, Habel LA, Nekhlyudov L, Achacoso N, Acton L, Schnitt SJ, **Schrag D**, Punglia RS. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. *Breast Cancer Res Treat*. 2016 Feb;155(3):541-9. PMID: 26843057.
173. Hassett MJ, Schymura MJ, Chen K, Boscoe FP, Gesten FC, **Schrag D**. Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. *Cancer*. 2016 Feb 1;122(3):420-31. PMID: 26536043.
174. Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, **Schrag D**, Basch E; National Cancer Institute PRO-CTCAE Study Group. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Health Qual Life Outcomes*. 2016 Feb 19;14(1):24. PMID: 26892667.
175. Yeh JM, Hur C, Ward Z, **Schrag D**, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. *Gut*. 2016 Apr;65(4):563-74. PMID: 25779597.
176. Lathan CS, Cronin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, **Schrag D**. Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. *J Clin Oncol*. 2016 May 20;34(15):1732-40. PMID: 26926678.
177. Basch E, Wood WA, **Schrag D**, Sima CS, Shaw M, Rogak LJ, Kris MG, Shouery M, Bennett A, Atkinson T, Pietanza MC. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. *Clin Trials*. 2016 Jun;13(3):331-7. PMID: 26542025.
178. **Schrag D**. Reimbursing Wisely? CMS's Experiment with Part B Drug Reimbursement. *N Engl J Med*. 2016 Jun 2;374(22):2101-5. PMID: 27248616.
179. Nipp RD, Zullig LL, Samsa G, Peppercorn JM, **Schrag D**, Taylor DH Jr, Abernethy AP, Zafar SY. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. *Psychooncology*. 2016 Jun;25(6):719-25. PMID: 26149817.
180. Jazić I, **Schrag D**, Sargent DJ, Haneuse S. Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. *J Natl Cancer Inst*. 2016 Jul 5;108(12). PMID: 27381741.
181. Popescu I, **Schrag D**, Ang A, Wong M. Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality: The Role of Physician-level Variations in Care. *Med Care*. 2016 Aug;54(8):780-8. PMID: 27326547.

182. Halpern MT, **Schrag D**. Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries. *Breast Cancer Res Treat*. 2016 Aug;158(3):573-81. PMID: 27422241.
183. Keating NL, Landrum MB, Huskamp HA, Kouri EM, Prigerson HG, **Schrag D**, Maciejewski PK, Hornbrook MC, Haggstrom DA. Dartmouth Atlas Area-Level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients? *Health Serv Res*. 2016 Aug;51(4):1584-94. PMID: 26799913.
184. Warren JL, Mariotto A, Melbert D, **Schrag D**, Doria-Rose P, Penson D, Yabroff KR. Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. *Med Care*. 2016 Aug;54(8):e47-54. PMID: 24374419.
185. Neuman HB, Rathouz PJ, Winslow E, Weiss JM, LoConte NK, Lin CP, Wurm M, Smith MA, **Schrag D**, Greenberg CC. Use of a novel statistical technique to examine the delivery of breast cancer follow-up care by different types of oncology providers. *J Eval Clin Pract*. 2016 Oct;22(5):737-44. PMID: 26991311.
186. Abdel-Misih SR, Wei L, Benson AB 3rd, Cohen S, Lai L, Skibber J, Wilkinson N, Weiser M, **Schrag D**, Bekaii-Saab T. Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. *J Natl Compr Canc Netw*. 2016 Dec;14(12):1528-1534. PMID: 27956537.
187. Arvold N, Cefalu M, Wang Y, Zigler C, **Schrag D**, Dominici F. Comparative effectiveness of radiology with vs. without temozolomide in older patients with glioblastoma. *J Neurooncol*. 2017 Jan;131(2):301-311. PMID: 27770280.
188. Punglia RS, Cronin AM, Uno H, Stout NK, Ozanne EM, Greenberg CC, Frank ES, **Schrag D**. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. *JAMA Oncol*. 2017 Jan 1;3(1):101-104. PMID: 27442038.
189. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, **Schrag D**, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. *J Clin Oncol*. 2017 Apr 1;35(10):1086-1095. PMID: 28135145.
190. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, **Schrag D**, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA*. 2017 Jun 20;317(23):2392-2401. PMID: 28632865.
191. Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarczyk RL, Cleeland CS, Sloan JA, **Schrag D**, Basch E. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. *Clin Trials*. 2017 Jun;14(3):255-263. PMID: 28545337.

192. Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, **Schrag D**, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. *J Clin Oncol*. 2017 Jul 1;35(19):2165-2172. PMID: 28489507.
193. Del Paggio JC, Sullivan R, **Schrag D**, Hopman WM, Azariah B, Pramesh CS, Tannock IF, Booth CM. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. *Lancet Oncol*. 2017 Jul;18(7):887-894. PMID: 28583794.
194. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, **Schrag D**. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. *JAMA*. 2017 Jul 11;318(2):197-198. PMID: 28586821.
195. Basch E, Dueck A, Rogak L, Minasian L, Kelly W, O'Mara A, Denicoff A, Seisler D, Atherton P, Paskett E, Carey L, Dickler M, Heist R, Himelstein A, Rugo H, Sikov W, Socinski M, Venook A, Weckstein D, Lake D, Biggs D, Freedman R, Kuzma C, Kirshner J, **Schrag D**. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. *JAMA Oncol*. 2017 Aug 1;3(8):1043-1050. PMID: 28208174.
196. Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, **Schrag D**, Hur C. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. *Am J Gastroenterol*. 2017 Aug;112(8):1256-1264. PMID: 28374815
197. Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, **Schrag D**, Fuchs CS. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. *Oncologist*. 2017 Aug;22(8):925-933. PMID: 28476943.
198. Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, **Schrag D**, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. *J Natl Cancer Inst*. 2017 Aug 1;109(8). PMID: 28376195.
199. Enzinger AC, Wind JK, Frank E, McCleary NJ, Porter L, Cushing H, Abbott C, Cronin C, Enzinger PC, Meropol NJ, **Schrag D**. A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. *Patient Educ Couns*. 2017 Aug;100(8):1527-1536. PMID: 28359659.
200. Yeh J, Tramontano A, Hur C, **Schrag D**. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. *Gastric Cancer*. 2017 Sep;20(5):811-824. PMID: 28205057.
201. Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, **Schrag D**, Kibel AS, Freedman ML. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. *Cancer*. 2017 Sep 15;123(18):3532-3539. PMID: 28608931.

202. Mack JW, Jacobson J, Frank D, Cronin AM, Horvath K, Allen V, Wind J, **Schrag D**. Evaluation of Patient and Family Outpatient Complaints as a Strategy to Prioritize Efforts to Improve Cancer Care Delivery. *J Qual Patient Saf*. 2017 Oct;43(10):498-507. PMID: 28942774.
203. Reyngold M, Niland J, Ter Veer A, Bekaii-Saab T, Lai L, Meyer JE, Nurkin SJ, **Schrag D**, Skibber JM, Benson AB, Weiser MR, Crane CH, Goodman KA. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. *Adv Radiat Oncol*. 2017 Oct 12;3(1):34-41. PMID: 29556578.
204. Keating NL, Huskamp HA, **Schrag D**, McWilliams JM, McNeil BJ, Landon BE, Chernew ME, Normand ST. Diffusion of Bevacizumab Across Oncology Practices: An Observational Study. *Med Care*. 2018 Jan;56(1):69-77. PMID: 29135615.
205. Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, **Schrag D**, Hur C. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. *Cancer Med*. 2018 Feb;7(2):525-535. PMID: 29322643.
206. Hassett MJ, Jiang W, Hughes ME, Edge S, Javid SH, Niland JC, Theriault R, Wong YN, **Schrag D**, Punglia RS. Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. *J Natl Compr Canc Netw*. 2018 Apr;16(4):387-394. PMID: 29632058.
207. Selvaraj S, Bhatt DL, Claggett B, Djoussé L, Shah SJ, Chen J, Imran TF, Qazi S, Sesso HD, Gaziano JM, **Schrag D**. Lack of Association Between Heart Failure and Incident Cancer. *J Am Coll Cardiol*. 2018 Apr 10;71(14):1501-1510. PMID: 29622155.
208. Lam MB, Li L, Cronin A, **Schrag D**, Chen AB. Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer. *Adv Radiat Oncol*. 2018 Apr 23;3(3):382-390. PMID: 30202806.
209. Tramontano AC, Nipp R, Mercaldo ND, Kong CY, **Schrag D**, Hur C. Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. *Dig Dis Sci*. 2018 Apr 23;3(3):382-390. PMID: 30109578
210. Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, **Schrag D**, Venook A, McKellar D, Winchester DP, Chang GJ. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer. Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group. *JAMA*. 2018 May 22;319(20):2104-2115. PMID: 29800181.
211. Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, **Schrag D**, Wei LJ. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. *JAMA Oncol*. 2018 Jun 1;4(6):881-882. PMID: 29801103.
212. Rebbeck T, Burns-White K, Chan A, Emmons K, Freedman M, Hunter D, Kraft P, Laden F, Mucci L, Parmigiani G, **Schrag D**, Syngal S, Tamimi R, Viswanath V, Yurgelun M, Garber J. Precision Prevention and Early Detection of Cancer: Fundamental Principles. *Cancer Discov*. 2018 Jul;8(7):803-811. PMID: 29907587.

213. Keating NL, Huskamp HA, Kouri E, **Schrag D**, Hornbrook MC, Haggstrom DA, Landrum MB. Factors Contributing to Geographic Variation In End-Of-Life Expenditures For Cancer Patients. *Health Aff (Millwood)*. 2018 Jul;37(7):1136-1143. PMID: 29985699.
214. Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, **Schrag D**, Dueck AC, Abernethy AP. Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. *JMIR Hum Factors*. 2018 Jul 16;5(3). PMID: 30012546.
215. McCleary NJ, Greenberg TL, Barysaukas CM, Guerette EJ, Hassan M, Jacobson JO, **Schrag D**. Oncology Patient Portal Enrollment at a Comprehensive Cancer Center: A Quality Improvement Initiative. *J Oncol Pract*. 2018 Aug;14(8). PMID: 30096276.
216. Chen CT, Li L, Brooks G, Hassett M, **Schrag D**. Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. *Health Serv Res*. 2018 Aug;53(4):2118-2132. PMID: 28748564.
217. Chen AB, Li L, Cronin AM, Brooks GA, Kavanagh BD, **Schrag D**. Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter? *Health Serv Res*. 2018 Aug;53 Suppl 1(Suppl Suppl 1):3227-3244. PMID: 28858372.
218. Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, **Schrag D**. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. *J Clin Oncol*. 2018 Sept 11; JCO2018788620. PMID: 30204536.
219. Haneuse S, Dominici F, Normand S, **Schrag D**. Assessment of Between-Hospital Variation in Readmission and Mortality After Cancer Surgical Procedures. *JAMA Net*. 2018 Oct 5;1(6): e183038. PMID: 30646221.
220. Brooks GA, Austin AM, Uno H, Dragnev K, Tosteson A, **Schrag D**. Hospitalization and Survival of Medicare Patients Treated with Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Non-squamous, Non-Small Cell Lung Cancer. *JAMA Net*. 2018 Oct 5;1(6). PMID: 30646220.
221. Kehl KL, Lathan CS, Johnson BE, **Schrag D**. Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. *J Natl Cancer Inst*. 2019 Apr 1;111(4):431-434. PMID: 30576459.
222. Chung AE, Shoenbill K, Mitchell SA, Dueck AC, **Schrag D**, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Am Med Inform Assoc*. 2019 Apr 1;26(4):276-285. PMID: 30840079.

223. **Schrag D**, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). *Clin Trials*. 2019 Apr;16(2):165-175. PMID: 30688523.
224. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, **Schrag D**, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. *JAMA*. 2019 Apr 9;321(14):1370-1379. PMID: 30964527.
225. Brooks GA, Uno H, Aiello Bowles EJ, Menter AR, O'Keeffe-Rosetti M, Tosteson ANA, Ritzwoller DP, **Schrag D**. Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data. *JCO Clin Cancer Inform*. 2019 Apr;3:1-10. PMID: 30995122.
226. Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, **Schrag D**. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. *Cancer Immunol Immunother*. 2019 Jun;68(6):917-926. PMID: 30877325.
227. Mossanen M, Krasnow RE, Zlatev DV, Tan WS, Preston MA, Trinh QD, Kibel AS, Sonpavde G, **Schrag D**, Chung BI, Chang SL. Examining the relationship between complications and perioperative mortality following radical cystectomy: A population-based analysis. *BJU Int*. 2019 Jul;124(1):40-46. PMID: 30499636.
228. Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, **Schrag D**, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. *Oncologist*. 2019 Jul;24(7):945-954. PMID: 30559125.
229. Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, **Schrag D**, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. *Cancer*. 2019 Jul 1;125(13):2213-2221. PMID: 30913304.
230. Kehl KL, Elmarakeby H, Nishino M, Van Allen EM, Lepisto EM, Hassett MJ, Johnson BE, **Schrag D**. Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. *JAMA Oncol*. 2019 Jul 25;5(10):1421-1429. PMID: 31343664.
231. Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, **Schrag D**, Miksad RA. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. *Adv Ther*. 2019 Aug;36(8):2122-2136. PMID: 31140124.

232. Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, **Schrag D**, Khozin S, Capra WB, Taylor MD, Abernethy AP. Characterizing the Feasibility and Performance of Real-World Tumor Progression Find Points and Their Association with Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. *JCO Clin Cancer Inform*. 2019 Aug;3:1-13. PMID: 31403818.
233. Uno H, **Schrag D**, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Events Outcomes. *JNCI Cancer Spectr*. 2019 Aug 1;3(4):pkz058. PMID: 32337484.
234. Ivatury SJ, Wong SL, **Schrag D**. Patient-Reported Outcomes-Bench to Bedside. *Ann Surg Oncol*. 2019 Nov 18;10.1234-019-07920-9. PMID: 31741111.
235. Kehl KL, Hassett MJ, **Schrag D**. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. *Cancer Med*. 2020 Mar;9(6):2019-2029. PMID: 31989786.
236. Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, Andre F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, **Schrag D**, Hyman DM, Genie Consortium AP. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinic-genomic registry. *Cancer Discov*. 2020 Apr;10(4):526-535. PMID: 31924700.
237. J Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, **Schrag D**, Miksad RA. *Real World RECIST Adv Ther*. 2020 Apr;37(4):1691-1693. PMID: 32056085.
238. Milligan MG, Cronin AM, Colson Y, Kehl K, Yeboa DN, **Schrag D**, Chen AB. Overuse of Diagnostic Brain Imaging Among Patients With Stage IA Non-Small Cell Lung Cancer. *J Natl Compr Canc Netw*. 2020 May;18(5):547-554. PMID: 32380461.
239. Kehl KL, **Schrag D**, Hassett MJ, Uno H. Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer. *JAMA Netw Open*. 2020 Jun 1;3(6):e206976. PMID: 32511717.
240. Leiter RE, Santus E, Jin Z, Lee K, Yusuf M, Chien I, Ramaswamy A, Moseley ET, Qian Y, **Schrag D**, Lindvall C.J. Deep natural language processing to identify symptom documentation in clinical notes for patients with heart failure undergoing cardiac resynchronization therapy. *J Pain Symptom Manage*. 2020 Jun 22;S0885-3924(20)30524-8. PMID: 32585181.
241. Enzinger AC, Uno H, McCleary N, Frank E, Sanoff H, Van Loon K, Matin K, Bullock A, Cronin C, Cibotti H, Bagley J, **Schrag D**. Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer: A Randomized Clinical Trial. *JAMA Oncol*. 2020 Aug 1;6(8):1265-1270. PMID: 32672806.
242. Enzinger AC, Uno H, McCleary N, Frank E, Sanoff H, Van Loon K, Matin K, Bullock A, Cronin C, Bagley J, **Schrag D**. The Effect of Disclosing Life Expectancy Information on Patients' Prognostic Understanding: Secondary Outcomes From a Multicenter Randomized Trial. *J Pain Symptom Manage*. 2020 Aug 7;S0885-3924(20)30636-9. PMID: 32777456.

243. Kehl K, Xu W, Lepisto E, Elmarakeby H, Hassett MJ, Van Ellen EM, Johnson BE, **Schrag D**. Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. *JCO Clin Cancer Inform*. 2020 Aug;4:680-690. PMID: 32755459.
244. Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, **Schrag D**, Kuntz KM. Estimating population-based recurrence rates of colorectal cancer over time in the United States. *Cancer Epidemiol Biomarkers Prev*. 2020 Sep 30;cebp.0490.2020. PMID: 32998946.
245. Goyal L, Chaudhary SP, Kwak EL, Abrams TA, Carpenter AN, Wolpin BM, Wadlow RC, Allen JN, Heist R, McCleary NJ, Chan JA, Goessling W, **Schrag D**, Ng K, Enzinger PC, Ryan DP, Clark JW. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. *Invest New Drugs*. 2020 Oct;38(5):1533-1539. PMID: 31898183.
246. Basch E, Stover AM, **Schrag D**, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears PA, Jonsson M, Bennett AV, Mody G, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Kottschade LA, Charlot M, Weiss A, Bruner D, Dueck AC. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. *JCO Clin Cancer Inform*. 2020 Oct;4:947-957. PMID: 33112661.
247. Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, **Schrag D**, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JA. Effect of High-Dose vs Standard-Dose Vitamin D₃ Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. *Cancers (Basel)*. 2020 Nov 20;12(11):3451. PMID: 33233566. PMCID: PMC7699725.
248. Manz C, **Schrag D**. Racial disparities in colorectal cancer recurrence and mortality: equitable care, inequitable outcomes? *J Natl Cancer Inst*. 2020 Nov 24 ;djaa186. PMID: 33231610.
249. Kehl KL, Riely GJ, Lepisto EM, Lavery JA, Warner JL, LeNoue-Newton ML, Sweeney SM, Rudolph JE, Brown S, Yu C, Bedard PL, **Schrag D**, Panageas KS; American Association of Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Consortium. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. *JAMA Netw Open*. 2021 Jul 1;4(7):e2117547. PMID: 34309669; PMCID: PMC8314138.
250. Chen AB, Niu J, Cronin AM, Shih YT, Giordano S, **Schrag D**. Variations in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists. *J Natl Compr Canc Netw*. 2021 Feb 12;19(4):421-431. PMID: 33578375.
251. Basch E, Becker C, Rogak LJ, **Schrag D**, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Composite grading algorithm for the National Cancer

Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Clin Trials*. 2021 Feb;18(1):104-114. PMID: 33258687. PMCID: PMC7878323.

252. Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, **Schrag D**, Janne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. *Cancer Discov*. 2021 Apr 29: candisc.1669.2020. PMID: 33926920
253. Haeuser L, Marchese M, **Schrag D**, Trinh QD, Chang SL, Kibel AS, Gore JL, Noldus J, Mossanen M. The impact of smoking on radical cystectomy complications increases in elderly patients. *Cancer*. 2021 May; 1;127(9):1387-1394. PMID: 33351967.
254. Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, **Schrag D**. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients with Advanced Non-Small Cell Lung Cancer. *JAMA Netw Open*. 2021 May 3;4(5): e2111113. PMID: 34019086.
255. Shih YT, Xu Y, Zhao H, **Schrag D**, Yao J. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. *JNCI Cancer Spectr*. 2021 May 18;5(4):pkab045. PMID: 34350376; PMCID: PMC8328094.
256. Kehl KL, Groha S, Lepisto EM, Elmarakeby H, Lindsay J, Gusev A, Van Allen EM, Hassett MJ, **Schrag D**. Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. *JCO Clin Cancer Inform*. 2021 Jun; 5:622-630. PMID: 34097438. PMCID: PMC8240790
257. Nadauld LD, McDonnell CH 3rd, Beer TM, Liu MC, Klein EA, Hudnut A, Whittington RA, Taylor B, Oxnard GR, Lipson J, Lopatin M, Shaknovich R, Chung KC, Fung ET, **Schrag D**, Marinac CR. The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. *Cancers (Basel)*. 2021 Jul 13;13(14):3501. PMID: 34298717; PMCID: PMC8304888.
258. Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohschein IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, **Schrag D**, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPI-AKI Consortium Investigators. Acute kidney injury in patients treated with immune checkpoint inhibitors. *J Immunother Cancer*. 2021 Oct;9(10): e003467. PMID: 34625513.

259. Manz CR, Odayar VS, **Schrag D**. Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review. *Cancer Med*. 2021 Oct;10(20):72777288. PMID: 34477309.
260. Mody GN, Stover AM, Wang M, King-Kallimanis BL, Jansen J, Henson S, Chung AE, Jonsson M, Bennett A, Smith AB, Wood WA, Deal A, Ginos B, Dueck AC, **Schrag D**, Basch E. Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39). *Lung Cancer*. 2021 Dec;162:1-8. PMID: 34634754
261. Weeks LD, Marinac CR, Redd RA, Abel GA, Lin AE, Agrawal M, Stone RM, **Schrag D**, Ebert BL. Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *Blood*. 2021 Dec 7: Blood.2021 PMID: 34875037.
262. Kehl KL, Xu W, Gusev A, Bakouny Z, Choueiri TK, Riaz IB, Elmarakeby H, Van Allen EM, **Schrag D**. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. *Nat Commun*. 2021 Dec 15;12(1):7304. PMID: 34911934; PMCID: PMC8674229.
263. Mehtsun WT, McCleary NJ, Maduekwe UN, Wolpin BM, **Schrag D**, Wang J. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. *JAMA Oncol*. 2022 Jan 1;8(1):88-95. PMID: 34854874; PMCID: PMC8640950.
264. Hassett MJ, Cronin C, Tsou TC, Wedge J, Bian J, Dizon DS, Hazard-Jenkins H, Osarogiagbon RU, Wong S, Basch E, Austin T, McCleary N, **Schrag D**. eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. *JCO Clin Cancer Inform*. 2022 Jan; 6: e2100137. PMID: 34985914.
265. Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, **Schrag D**, Panageas KS. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. AACR Project GENIE Consortium. *JAMA Oncol*. 2022 Feb 1;8(2):287-291. PMID: 34734967
266. Lavery JA, Lepisto EM, Brown S, Rizvi H, McCarthy C, LeNoue-Newton M, Yu C, Lee J, Guo X, Yu T, Rudolph J, Sweeney S; AACR Project GENIE Consortium, Park BH, Warner JL, Bedard PL, Riely G, **Schrag D**, Panageas KS. A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. *JCO Clin Cancer Inform*. 2022 Feb; 6: e2100105. PMID: 35192403
267. Alarid-Escudero F, **Schrag D**, Kuntz KM. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. *Value Health*. 2022 Mar;25(3):409-418. Epub 2021 Nov 2. PMID: 35227453
268. Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, **Schrag D**, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer:

- BOND-3, an ACCRU Network Randomized Clinical Trial. *Oncologist*. 2022 Apr 5;27(4):292-298. PMID: 35380713; PMCID: PMC8982431.
269. LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, **Schrag D**, Lepisto EM, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Eli LD, Xu F, Mann G, Lalani AS, Ye F, Micheel CM, Arnedos M. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. *Clin Cancer Res*. 2022 May 13;28(10):2118-2130. PMID: 35190802.
270. Frere C, Farge D, **Schrag D**, Prata PH, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. *J Hematol Oncol*. 2022 May 21;15(1):69. PMID: 35598026.
271. Stavrou E, Qiu J, Zafar A, Tramontano AC, Isakoff S, Winer E, **Schrag D**, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. *JCO Oncol Pract*. 2022 Jun 7:OP2200072. PMID: 35671420. PMCID: PMC9509057.
272. Papke DJ, Lindeman NI, **Schrag D**, Iorgulescu JB. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev*. 2022 Jun 29;epi.22.0279. PMID: 35767976.
273. Basch E, **Schrag D**, Henson S, Jansen J, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Samuel-Ryals CA, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Dueck AC. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. *JAMA*. 2022 Jun 28;327(24):2413-2422. PMID: 35661856; PMCID: PMC9168923.
274. Hassett MJ, Wong S, Osarogiagbon RU, Bian J, Dizon DS, Jenkins HH, Uno H, Cronin C, **Schrag D**; SIMPRO Co-Investigators. Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. *Trials*. 2022 Jun 16;23(1):506. PMID: 35710449; PMCID: PMC9202326.
275. Yu JB, **Schrag D**, Robin Yabroff K. Health Economics Research in Cancer Treatment: Current Challenges and Future Directions. *J Natl Cancer Inst Monogr*. 2022 Jul 5;2022(59):51-56. PMID: 35788370.
276. Haneuse S, **Schrag D**, Dominici F, Normand SL, Lee KH. MEASURING PERFORMANCE FOR END-OF-LIFE CARE. *Ann Appl Stat*. 2022 Sep;16(3):1586-1607. PMID: 36483542; PMCID: PMC9728673.
277. Garcia Farina E, Rowell J, Revette A, Haakenstad EK, Cleveland JLF, Allende R, Hassett M, **Schrag D**, McCleary NJ. Barriers to Electronic Patient-Reported Outcome Measurement Among Patients with Cancer and Limited English Proficiency. *JAMA Netw Open*. 2022 Jul 1;5(7):e2223898. PMID: 35867056; PMCID: PMC9308052.

278. Merola D, Schneeweiss S, **Schrag D**, Lii J, Lin KJ. An algorithm to predict data completeness in oncology electronic medical records for comparative effectiveness research. *Ann Epidemiol*. 2022 Dec;76:143-149. PMID: 35878784; PMCID: PMC9741728.
279. Manz CR, Tramontano AC, Uno H, Parikh RB, Bekelman JE, **Schrag D**. Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies. *JAMA Netw Open*. 2022 Sep 1;5(9):e2234161. PMID: 36173630; PMCID: PMC9523492.
280. Weiser MR, Chou JF, Kim JK, Widmar M, Wei IH, Pappou EP, Smith JJ, Nash GM, Paty PB, Cercek A, Saltz LB, Romesser PB, Crane CH, Garcia-Aguilar J, **Schrag D**, Gönen M. A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management. *JAMA Netw Open*. 2022 Sep 1;5(9):e2233859. PMID: 36173634; PMCID: PMC9523500.
281. Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, Xu W, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, Choueiri TK, **Schrag D**, Carrot-Zhang J, Gusev A. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. *Cancer Cell*. 2022 Oct 10;40(10):1161-1172.e5. PMID: 36179682; PMCID: PMC9559771.
282. Pappou EP, Temple LK, Patil S, Smith JJ, Wei IH, Nash GM, Guillem JG, Widmar M, Weiser MR, Paty PB, **Schrag D**, Garcia-Aguilar J. Quality of life and function after rectal cancer surgery with and without sphincter preservation. *Front Oncol*. 2022 Oct 21;12:944843. PMID: 36353560; PMCID: PMC9639454.
283. Schumacher JR, Neuman HB, Yu M, Vanness DJ, Si Y, Burnside ES, Ruddy KJ, Partridge AH, **Schrag D**, Edge SB, Zhang Y, Jacobs EA, Havlena J, Francescatti AB, Winchester DP, McKellar DP, Spears PA, Kozower BD, Chang GJ, Greenberg CC; Alliance ACS-CRP CDR Breast Cancer Surveillance Working Group. Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01). *J Natl Cancer Inst*. 2022 Oct 6;114(10):1371-1379. PMID: 35913454; PMCID: PMC9552308.
284. Merola D, Young J, **Schrag D**, Lin KJ, Robert N, Schneeweiss S. Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation. *Clin Epidemiol*. 2022 Oct 10;14:1135-1144. PMID: 36246306; PMCID: PMC9563733.
285. Merola D, Young J, **Schrag D**, Lin KJ, Alwardt S, Schneeweiss S. Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA-2 trial. *Pharmacoepidemiol Drug Saf*. 2023 Apr;32(4):426-434. PMID: 36345809; PMCID: PMC10038825.
286. Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, **Schrag D**, LeNoue-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. *Sci Rep*. 2022 Nov 9;12(1):19055. PMID: 36351964; PMCID: PMC9646734.

287. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, **Schrag D**, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med*. 2022 Dec;28(12):2584-2591. PMID: 36526723.
288. Keller RB, Mazor T, Sholl L, Aguirre AJ, Singh H, Sethi N, Bass A, Nagaraja AK, Brais LK, Hill E, Hennessey C, Cusick M, Del Vecchio Fitz C, Zwiesler Z, Siegel E, Ovalle A, Trukhanov P, Hansel J, Shapiro GI, Abrams TA, Biller LH, Chan JA, Cleary JM, Corsello SM, Enzinger AC, Enzinger PC, Mayer RJ, McCleary NJ, Meyerhardt JA, Ng K, Patel AK, Perez KJ, Rahma OE, Rubinson DA, Wisch JS, Yurgelun MB, Hassett MJ, MacConaill L, **Schrag D**, Cerami E, Wolpin BM, Nowak JA, Giannakis M. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. *JCO Precis Oncol*. 2023 Jan;7:e2200342. PMID: 36634297; PMCID: PMC9929103.
289. Moon I, LoPiccolo J, Baca SC, Sholl LM, Kehl KL, Hassett MJ, Liu D, **Schrag D**, Gusev A. Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients. *Res Sq [Preprint]*. 2023 Jan 10:rs.3.rs-2450090. PMID: 36711812; PMCID: PMC9882677.
290. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, **Schrag D**, Enzinger AC. Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. *J Cancer Educ*. 2023 Feb 11. PMID: 36773178.
291. Kehl KL, Uno H, Gusev A, Groha S, Brown S, Lavery JA, **Schrag D**, Panageas KS. Elucidating Analytic Bias Due to Informative Cohort Entry in Cancer Clinico-genomic Datasets. *Cancer Epidemiol Biomarkers Prev*. 2023 Mar 6;32(3):344-352. PMID: 36626408; PMCID: PMC9992002.
292. Liddicoat Yamarik R, Chiu LA, Flannery M, Van Allen K, Adeyemi O, Cuthel AM, Brody AA, Goldfeld KS, **Schrag D**, Grudzen CR, On Behalf Of The EMPallA Investigators. Engagement, Advance Care Planning, and Hospice Use in a Telephonic Nurse-Led Palliative Care Program for Persons Living with Advanced Cancer. *Cancers (Basel)*. 2023 Apr 15;15(8):2310. PMID: 37190238; PMCID: PMC10136814.
293. Manz CR, Odayar VS, **Schrag D**. Cancer Screening Rates and Outcomes for Justice-Involved Individuals: A Scoping Review. *J Correct Health Care*. 2023 Jun;29(3):220-231. PMID: 37074345.
294. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, **Schrag D**. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). *J Clin Oncol*. 2023 Jun 4:JCO2300903. PMID: 37270691.
295. **Schrag D**, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. Preoperative Treatment of Locally Advanced Rectal Cancer. *N Engl J Med*. 2023 Jun 4. PMID: 37272534.

296. **Schrag D**, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, Drescher M, Jayaram N, Holmes C, Feldman L, Zattra O, Farrar-Muir H, Cronin C, Basch E, Weiss A, Connors JM; CANVAS Investigators. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. *JAMA*. 2023 Jun 13;329(22):1924-1933. PMID: 37266947; PMCID: PMC10265290.

Reviews and Editorials:

1. Garber JE, **Schrag D**. Testing for inherited cancer susceptibility. *JAMA*. 1996;275(24):1928-9. PMID: 8648875.
2. **Schrag D**, Weeks JC. Costs and cost-effectiveness of colorectal cancer prevention and therapy. *Semin Oncol*. 1999;26(5):561-8. PMID: 10528905.
3. **Schrag D**. Defining optimal treatment for stage II colon cancer: does decision analysis help? *Gastroenterology*. 1999;117(4):1005-8. PMID: 10500083.
4. Bach PB, **Schrag D**. Risk charts: putting cancer in context. *J Natl Cancer Inst*. 2002 Oct 16;94(20):1584-1586. PMID: 12381716.
5. Begg CB, **Schrag D**. Attribution of deaths following cancer treatment. *J Natl Cancer Inst*. 2002;94(14):1044-5. PMID: 12122090.
6. Bach PB, **Schrag D**, Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. *JAMA*. 2004;292(22):2765-70. PMID: 15585737.
7. Iasonos A, **Schrag D**, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol*. 2008 Mar 10;26(8):1364-70. PMID: 18323559.
8. **Schrag D**. Enhancing Cancer Registry Data to Promote Rational Health System Design. *J Natl Cancer Inst*. 2008;100(6):399-406. PMID: 18334703.
9. Yabroff KR, **Schrag D**. Challenges and opportunities for use of cost-effectiveness analysis. *J Natl Cancer Inst*. 2009;101(7):1161-3. PMID: 19666852.
10. **Schrag D**. Evaluating the impact of organizational changes in health care delivery: challenges in study design. *J Clin Oncol*. 2009;27(11):1744-5. PMID: 19273700.
11. Greenberg CC, Ashley SW, **Schrag D**. Centralization of Cancer Surgery: What Does It Mean for Surgical Training? *J Clin Oncol*. 2009;27(28):4671-8. PMID: 19720900.

12. Ng K, **Schrag D**. Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch? *J Clin Oncol*. 2010 May 24;28(20):3207-10. PMID: 20498398.
13. Lajous M, Mozaffarian D, Mozaffarian R, **Schrag D**, Adami HO. Lifestyle prescriptions for cancer survivors and their communities. *J Intern Med*. 2011 Jan;269(1):88-93. PMID: 21158981.
14. Weeks JC, Mack JW, **Schrag D**. Talking to Patients about Dying. *N Engl J Med*. 2013 Jan 31;368(5):480-1. PMID: 23363507.
15. **Schrag D**. Evolving role of neoadjuvant therapy in rectal cancer. *Curr Treat Options Oncol*. 2013 Sep;14(3):350-64. PMID: 23828092.
16. Weiser MR, Fichera A, **Schrag D**, Boughey JC, You YN. Progress in the PROSPECT trial: precision treatment for rectal cancer? *Bull Am Coll Surg*. 2015 Apr;100(4):51-2. PMID: 25939207.
17. **Schrag D**. Optimizing Treatment for Locally Advanced Pancreas Cancer: Progress but No Precision. *JAMA*. 2016 May 3;315(17):1837-1838. PMID: 27139054.
18. Schiff D, **Schrag D**. Living in the material world: tumor-treating fields at the top of the charts. *Neuro Oncol*. 2016 Aug;18(8):1033-4. PMID: 27382117.
19. Burstein HJ, **Schrag D**. Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? *JAMA*. 2017 Jan 3;317(1):30-32. PMID: 27918782.
20. Schwartzberg L, Kim ES, Liu D, **Schrag D**. Precision Oncology: Who, How, What, When, and When Not? *Am Soc Oncol Educ Book*. 2017. PMID: 28561651.
21. **Schrag D**, Basch E. Oncology in Transition: Changes, Challenges, and Opportunities. *JAMA*. 2018 Dec 4;320(21):2203-2204. PMID: 30419140.
22. Nass S, Rothenberg M, Pentz R, Hricak H, Abernethy A, Anderson K, Wagner Gee A, Harvey D, Piantadosi S, Bertagnolli M, **Schrag D**, Schilsky R. Accelerating anticancer drug development – opportunities and trade-offs. *Nat Rev Clin Oncol*. 2018 Dec;15(12):777-786. PMID: 30275514.
23. Taylor JW, Armstrong T, Kim AH, Venere M, Acquaye A, **Schrag D**, Wen PY. The lomustine crisis: awareness and impact of the 1500% price hike. *Neuro Oncol*. 2019 Jan 1;21(1):1-3. PMID: 30590836.
24. Basch E, **Schrag D**. The Evolving Uses of "Real-World" Data. *JAMA*. 2019 Apr 9;321(14):1359-1360. PMID: 30964515.

25. Ivatury SJ, Hazard-Jenkins HW, Brooks GA, McCleary NJ, Wong SL, **Schrag D**. Translation of Patient-Reported Outcomes in Oncology Clinical Trials to Everyday Practice. *Ann Surg Oncol*. 2020 Jan;27(1):65-72. PMID: 31452053.
26. Basch E, Wilfong L, **Schrag D**. Adding Patient-Reported Outcomes to Medicare's Oncology Value-Based Payment Model. *JAMA*. 2020 Jan 21;323(3):213-214. PMID: 31895416.
27. Haneuse S, **Schrag D**, Nevo D. Dual Outcome Intention-to-treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. *Am J Epidemiol*. 2020 Sep 1;189(9):982-984. PMID: 32314782.
28. **Schrag D**, Hershman DL, Basch E. Oncology Practice During the COVID-19 Pandemic. *JAMA*. 2020 May 26;323(20):2005-2006. PMID: 32282023.
29. Ng K, May FP, **Schrag D**. US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty. *JAMA*. 2021 May 18;325(19):1943-1945. PMID: 34003238
30. Biller LH, **Schrag D**. A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer-Reply. *JAMA*. 2021 Jun 15;325(23):2405. PMID: 34129001.
31. Stadler ZK, **Schrag D**. Genetic Testing for Cancer Susceptibility. *JAMA*. 2023 Jun 5. PMID: 37276548.

Chapters:

1. **Schrag D**, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays. *J Clin Oncol*. 2004;22(17):3631-38. PMID: 15289488.
2. Benson AB, **Schrag D**, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol*. 2004;22(16):3408-19. PMID: 15199089.
3. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, **Schrag D**, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. *J Natl Cancer Inst*. 2005;97(19):1407-27. PMID: 16204691.
4. Jeong SY, Chessin DB, **Schrag D**, Riedel E, Wong WD, Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst* 2005 Nov 16;97(22):1705-1706. PMID: 16288127.

5. Paskett ED, **Schrag D**, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and Leukemia Group B cancer control and health outcomes committee: origins and accomplishments. *Clin Cancer Res*. 2006 Jun 1;12 :3601s-3605s. PMID:16740792.
6. Nahas CS, Shia J, Joseph R, **Schrag D**, Minsky B, Weiser M, Guillem J, Paty P, Klimstra D, Tang L, Wong W, Temple L. Squamous-cell carcinoma of the rectum: a rare but curable tumor. *Dis Colon Rectum*. 2007 Sep;50(9):1393-1400. PMID: 17661147.
7. Desch CE, McNiff KK, Schneider EC, **Schrag D**, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY, Stewart AK, Edge SB. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. *J Clin Oncol*. 2008 Jul 20;26(21):3631-3637. PMID: 18640941.
8. Meropol NJ, **Schrag D**, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE. American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. *J Clin Oncol*. 2009;27(23):3868-74. PMID: 19581533.
9. Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, **Schrag D**, Schulman KA, Scott J. A Health Services Research Agenda for Cellular, Molecular, and Genomic Technologies in Cancer Care. *Pub Health Genomics*. 2009;12(4):233-44. PMID: 19367091.
10. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, **Schrag D**, Seidenfeld J, Benson AB 3rd. American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. *J Clin Oncol*. 2009;28(3):493-508. PMID: 19841322.
11. Burstein HJ, Mangu PB, Somerfield MR, **Schrag D**, Samson D, Holt L, Zelman D, Ajani JA, American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. *J Clin Oncol*. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
12. Kehl KL, Keating NL, Giordano SH, **Schrag D**. Insurance Networks and Access to Affordable Cancer Care. *J Clin Oncol*. 2019 Dec 5;JCO1901484. PMID: 31804867.
13. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, **Schrag D**, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. *Nat Rev Clin Oncol*. 2020 Dec;17(12):757-770. PMID: 32632268.
14. Biller L, **Schrag D**. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. *JAMA*. 2021 Feb 16;325(7):669-685. PMID: 33591350.
15. National Academy of Medicine: Report of the Committee on Weight-Based Medications, *National Academy*, 2021.

16. Osarogiagbon RU, Mullangi S, Schrag D. Medicare Spending, Utilization, and Quality in the Oncology Care Model. *JAMA*. 2021 Nov 9;326(18):1805-1806. PMID: 34751724.

Educational Materials for Patients:

No materials below were sponsored by commercial entities.

2000	General care and regimen-specific patient educational materials at Memorial Sloan-Kettering Cancer Center	Developer of educational materials for general care and regimen-specific guidance for patients with gastrointestinal cancer used at MSKCC. (Institutional funding for this work)
2017	Chemotherapy informed consent videos	Developed a series of videos (part of a multi-component intervention) that describe chemotherapy from patient, caregiver and clinician perspectives. These include videos in Spanish that are tailored to the needs of the Hispanic population. These are now in use at centers across the US. (PCORI funding for this work)
2019	Symptom management Tip sheets for integration into the Epic HER	Developed a series of “tip sheets” for 56 common symptoms that occur following administration of cancer chemotherapy and/or after major surgery for cancer or benign conditions. I coordinated assembly of content and review by multi-disciplinary team including oncologists, surgeons, nurses and patient advocates. These materials are now in use at 6 cancer centers for supporting patient education and have been integrated into Epic’s foundation for dissemination across sites that run the Epic system. (NCI-funding for this work)
2019	Track your cancer journey	Developed tools for patients to track their cancer histories including treatments received, responses to treatment and tolerance of treatment to support patient-directed curation of clinical data. Software in development to support scalability. The system fulfills the need to understand cancer trajectories as patients transition across health care systems and clinicians. (Philanthropic funding for this work)

Articles and Other Media:

Numerous articles, interviews, and information products in the national and global popular and scientific media (on-line, in print, broadcast news, etc.) have covered my research; highlights (complete listing no longer maintained, available from web search) include:

1. Grady D. Scientists Do the Math to Fight Breast Cancer. *New York Times*. Science Times section. February 8, 2000.

2. Charlie Rose Science Series Explores Developments in Cancer Research. Episode 4 of Science Series to Examine Cancer, its Genetics, Prevention and Treatment. Filmed segment with host Charlie Rose. With co-host Sir Paul Nurse, Nobel Laureate, President of Rockefeller University, and leading experts. April 17, 2007.
3. The Aspen Ideas Festival. The future of health care July 5-7th, 2007. Public forum discussion Aspen Institute, Aspen Colorado.
4. Kolata G, Pollack A. Costly Cancer Drug Offers Hope, but Also a Dilemma. New York Times. July 6, 2008.
5. Honan D. Big Think Breakthroughs: Cancer. Big Think Knowledge Forum. September 22, 2011.
6. Schultz D. Many Terminal Cancer Patients Mistakenly Believe a Cure is Possible. National Public Radio (NPR). Segment on Shots, a Health News Program. November 2013 Recorded segment.
7. The New Yorker Festival 2013 Understanding the Affordable Care Act.
8. TEDMED: From Efficacy to Effectiveness to Implementation in Health Care Delivery
9. Davos Annual Meeting, Davos, Switzerland invited panelist 2014. Harnessing Electronic Health Records to Accelerate Research
10. Aspen Ideas Festival: Panelist: the Future of Precision Medicine 2015, Aspen, Colorado.
11. Quoted in more than 93 news items about the PROSPECT study from ASCO 2023, reaching a potential audience of 71 million. Coverage kicked off with a comprehensive story in the [New York Times](#) with additional top-tier and trade coverage in [HealthDay](#) (with syndication in [US News & World Report](#) and [WebMD](#)), [The Guardian](#) (UK), [The Telegraph](#) (UK), [Medscape](#), [MedPage Today](#), [SILIVE](#), [Becker's Hospital Review](#), [The ASCO Post](#), [Cure Today](#), and [Healio](#) among others.